var title_f25_57_26512="Wagner 1 foot ulcer";
var content_f25_57_26512=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F70998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F70998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Wagner grade 1 ulcer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 232px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Foot from a diabetic patient showing a superficial ulcer (Wagner grade 1) that involves the full thickness of the skin but no underlying tissues. This lesion healed quickly with rest and local foot care.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David McCulloch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_57_26512=[""].join("\n");
var outline_f25_57_26512=null;
var title_f25_57_26513="Morgan lens insertion";
var content_f25_57_26513=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 572px\">",
"   <div class=\"ttl\">",
"    Insertion of Morgan&reg; lens",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 552px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Solution acts as a cushion, suspending the Lens above the cornea and protecting injured surfaces from the eyelids.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: MorTan, Inc. Copyright &copy; 2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_57_26513=[""].join("\n");
var outline_f25_57_26513=null;
var title_f25_57_26514="Vulva hematoma and catheter";
var content_f25_57_26514=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar hematoma with foley catheter placed",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Emans SJ, Laufer MR. Emans, Laufer &amp; Goldstein&rsquo;s Pediatric&nbsp;and Adolescent Gynecology, 6th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_57_26514=[""].join("\n");
var outline_f25_57_26514=null;
var title_f25_57_26515="Electrocardiographic changes from tricyclic antidepressant";
var content_f25_57_26515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Electrocardiographic changes from tricyclic antidepressant overdose",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The QRS complex is prolonged with delayed right ventricular activation and intraventricular conduction delay, which results in rightward shift in the terminal 40 msec frontal plane QRS vector. In qualitative terms, this shift manifests as a deep, slurred S wave in leads I and AVL, and an R wave in lead AVR (blue arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_57_26515=[""].join("\n");
var outline_f25_57_26515=null;
var title_f25_57_26516="Laparoscopic salpingectomy";
var content_f25_57_26516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Laparoscopic total salpingectomy using electrosurgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 423px; height: 484px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bipolar forceps are used to fulgurate the mesosalpinx, which is followed by using scissors to cut the mesosalpinx.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_57_26516=[""].join("\n");
var outline_f25_57_26516=null;
var title_f25_57_26517="Negative margins in thymoma";
var content_f25_57_26517=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Predominantly lymphocytic, invasive thymoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This thymoma is predominantly composed of lymphocytes with scattered epithelial cells; it invades the surrounding mediastinal fat tissue but does not reach the inked surgical margin. (Hematoxylin and eosin, magnification 25x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Travis, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_57_26517=[""].join("\n");
var outline_f25_57_26517=null;
var title_f25_57_26518="Amphotericin B cholesteryl sulfate complex: Drug information";
var content_f25_57_26518=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"18\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amphotericin B cholesteryl sulfate complex: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/59/38836?source=see_link\">",
"    see \"Amphotericin B cholesteryl sulfate complex: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F134753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Amphotec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F134754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Amphotec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F134772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent, Parenteral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F134757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Aspergillosis (invasive), treatment:",
"     </b>",
"     <i>",
"      Usual dosage range:",
"     </i>",
"     3-4 mg/kg/day.",
"     <b>",
"      Note:",
"     </b>",
"     6 mg/kg/day has been used for treatment of life-threatening invasive aspergillosis in immunocompromised patients (Bowden, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Premedication:",
"      </i>",
"     </b>",
"     For patients who experience chills, fever, hypotension, nausea, or other nonanaphylactic infusion-related immediate reactions, premedicate with the following drugs 30-60 minutes prior to drug administration: A nonsteroidal with or without diphenhydramine",
"     <b>",
"      or",
"     </b>",
"     acetaminophen with diphenhydramine",
"     <b>",
"      or",
"     </b>",
"     hydrocortisone 50-100 mg with or without a nonsteroidal and diphenhydramine (Paterson, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Test dose:",
"      </i>",
"     </b>",
"     For patients receiving their first dose in a new treatment course, a small amount (10 mL of the final preparation, containing between 1.6-8.3 mg) infused over 15-30 minutes is recommended. The patient should then be observed for an additional 30 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F134766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F134758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F134738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amphotec&reg;: 50 mg [contains edetate disodium, lactose 950 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amphotec&reg;: 100 mg [contains edetate disodium, lactose 1900 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F134723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F134741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initially infuse at 1 mg/kg/hour. Rate of infusion may be increased with subsequent doses as patient tolerance allows (minimum infusion time: 2 hours). For a patient who experiences chills, fever, hypotension, nausea, or other nonanaphylactic infusion-related reactions, premedicate with the following drugs 30-60 minutes prior to drug administration: A nonsteroidal with or without diphenhydramine",
"     <b>",
"      or",
"     </b>",
"     acetaminophen with diphenhydramine",
"     <b>",
"      or",
"     </b>",
"     hydrocortisone 50-100 mg with or without a nonsteroidal and diphenhydramine (Paterson, 2008). If the patient experiences rigors during the infusion, meperidine may be administered. If severe respiratory distress occurs, the infusion should be immediately discontinued.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F134778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W;",
"     <b>",
"      incompatible",
"     </b>",
"     with NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, aminophylline, cefoxitin, clindamycin, dexamethasone sodium phosphate, fentanyl, furosemide, ganciclovir, granisetron, hydrocortisone sodium succinate, ifosfamide, lorazepam, mannitol, methotrexate, methylprednisolone sodium succinate, nitroglycerin, sufentanil, trimethoprim and sulfamethoxazole, vinblastine, vincristine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Alfentanil, amikacin, ampicillin, ampicillin/sulbactam, atenolol, aztreonam, buprenorphine, butorphanol, calcium chloride, calcium gluconate, carboplatin, cefazolin, cefepime, ceftazidime, ceftriaxone, chlorpromazine, cimetidine, ciprofloxacin, cisatracurium, cisplatin, cyclophosphamide, cyclosporine, cytarabine, diazepam, digoxin, diphenhydramine, dobutamine, dopamine, doxorubicin, doxorubicin liposome, droperidol, enalaprilat, esmolol, famotidine, fluconazole, fluorouracil, gentamicin, haloperidol, heparin, hydromorphone, hydroxyzine, imipenem/cilastatin, labetalol, leucovorin calcium, lidocaine, magnesium sulfate, meperidine, mesna, metoclopramide, metoprolol, metronidazole, miconazole, midazolam, mitoxantrone, morphine, nalbuphine, naloxone, ondansetron, paclitaxel, pentobarbital, phenobarbital, phenytoin, piperacillin, piperacillin/tazobactam, potassium chloride, prochlorperazine, promethazine, propranolol, ranitidine, remifentanil, sodium bicarbonate, ticarcillin/clavulanate potassium, tobramycin, vancomycin, vecuronium, verapamil, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cytarabine, doripenem.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F134740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of invasive aspergillosis in patients who have failed amphotericin B deoxycholate treatment, or who have renal impairment or experience unacceptable toxicity which precludes treatment with amphotericin B deoxycholate in effective doses.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F134769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Effective in patients with serious",
"     <i>",
"      Candida",
"     </i>",
"     species infections",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F134780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lipid-based amphotericin formulations (Amphotec&reg;) may be confused with conventional formulations (Amphocin&reg;, Fungizone&reg;)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Large overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products. Single daily doses of conventional amphotericin formulation never exceed 1.5 mg/kg.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F134770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills, fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hyperbilirubinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     5% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain, facial edema, hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Abnormal thinking, headache, insomnia, somnolence, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash, sweating",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia, hypocalcemia, hypomagnesemia, hypophosphatemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal enlargement, abdominal pain, diarrhea, dry mouth, hematemesis, jaundice, nausea, stomatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia, hemorrhage, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, liver function test abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, rigor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough increased, dyspnea, epistaxis, hypoxia, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &lt;5% (Limited to important or life-threatening): Acidosis, arrhythmias (both atrial and ventricular), cardiac arrest, gastrointestinal hemorrhage, heart failure, injection site pain/reaction, liver failure, oliguria, pleural effusion, renal failure, seizure, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Amphotericin B colloidal dispersion has an improved therapeutic index compared to conventional amphotericin B, and has been used safely in patients with amphotericin B-related nephrotoxicity; however, continued decline of renal function has occurred in some patients.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F134744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amphotericin B or any component of the formulation (unless the benefits outweigh the possible risk to the patient)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F134727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis: Has been reported with amphotericin B-containing drugs; facilities for cardiopulmonary resuscitation should be available during administration due to the possibility of anaphylactic reaction. If severe respiratory distress occurs, the infusion should be immediately discontinued; the patient should not receive further infusions. During the initial dosing, the drug should be administered under close clinical observation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infusion reactions: Acute infusion reactions, sometimes severe, may occur 1-3 hours after starting infusion. These reactions are usually more common with the first few doses and generally diminish with subsequent doses. Pretreatment with antihistamines/corticosteroids and/or decreasing the rate of infusion can be used to manage reactions. Avoid rapid infusion.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F134732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Amphotericin B may enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May diminish the therapeutic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Amphotericin B may enhance the nephrotoxic effect of Colistimethate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Amphotericin B may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flucytosine: Amphotericin B may enhance the adverse/toxic effect of Flucytosine. This may be related to the adverse effects of amphotericin B on renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gallium Nitrate: Amphotericin B may enhance the nephrotoxic effect of Gallium Nitrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F134734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13314096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Amphotericin crosses the placenta and enters the fetal circulation. Amphotericin B is recommended for the treatment of serious systemic fungal diseases in pregnant women; refer to current guidelines (King, 1998).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F134762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F134747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if amphotericin is excreted into breast milk. Due to its poor oral absorption, systemic exposure to the nursing infant is expected to be decreased; however, because of the potential for toxicity, breast-feeding is not recommended (Mactal-Haaf, 2001).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Amphotec Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $93.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1): $160.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F134736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests, serum electrolytes (especially potassium and magnesium), BUN, serum creatinine, CBC, prothrombin time; temperature, I/O; signs of hypokalemia (muscle weakness, cramping, drowsiness, ECG changes)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F134748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Amphocil (AT, AU, BR, CZ, DK, FI, GB, HK, HN, IL, IT, MX, MY, NL, SE, TH, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F134726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to ergosterol altering cell membrane permeability in susceptible fungi and causing leakage of cell components with subsequent cell death. Proposed mechanism suggests that amphotericin causes an oxidation-dependent stimulation of macrophages (Lyman, 1992).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F134743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Total volume increases with higher doses, reflects increasing uptake by tissues (with 4 mg/kg/day = 4 L/kg); predominantly distributed in the liver; concentrations in kidneys and other tissues are lower than observed with conventional amphotericin B",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~28 hours; prolonged with higher doses",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bowden R, Chandrasekar P, White MH, et al, &ldquo;A Double-Blind, Randomized, Controlled Trial of Amphotericin B Colloidal Dispersion versus Amphotericin B for Treatment of Invasive Aspergillosis in Immunocompromised Patients,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2002, 35(4):359-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26518/abstract-text/12145716/pubmed\" id=\"12145716\" target=\"_blank\">",
"        12145716",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26518/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chapman SW, Dismukes WE, Proia LA, et al, \"Clinical Practice Guidelines for the Management of Blastomycosis: 2008 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2008, 46(12):1801-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26518/abstract-text/18462107/pubmed\" id=\"18462107\" target=\"_blank\">",
"        18462107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Edwards JE Jr, Bodey GP, Bowden RA, et al, &ldquo;International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1997, 25(1):43-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26518/abstract-text/9243032/pubmed\" id=\"9243032\" target=\"_blank\">",
"        9243032",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eggimann P, Francioli P, Bille J, et al, &ldquo;Fluconazole Prophylaxis Prevents Intra-abdominal Candidiasis in High-Risk Surgical Patients,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1999, 27(6):1066-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26518/abstract-text/10397206/pubmed\" id=\"10397206\" target=\"_blank\">",
"        10397206",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fichtenbaum CJ, Zackin R, Rajicic N, et al, &ldquo;Amphotericin B Oral Suspension for Fluconazole-Refractory Oral Candidiasis in Persons With HIV Infection. Adult AIDS Clinical Trials Group Study Team 295,&rdquo;",
"      <i>",
"       AIDS",
"      </i>",
"      , 2000, 14(7):845-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26518/abstract-text/10839593/pubmed\" id=\"10839593\" target=\"_blank\">",
"        10839593",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Galgiani JN, Ampel NM, Blair JE, et al, \"Coccidioidomycosis,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(9):1217-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26518/abstract-text/16206093/pubmed\" id=\"16206093\" target=\"_blank\">",
"        16206093",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hiemenz JW and Walsh TJ, &ldquo;Lipid Formulations of Amphotericin B: Recent Progress and Future Directions,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1996, 22(Suppl 2):133-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26518/abstract-text/8824978/pubmed\" id=\"8824978\" target=\"_blank\">",
"        8824978",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kauffman CA, Bustamante B, Chapman SW, et al, \"Clinical Practice Guidelines for the Management of Sporotrichosis: 2007 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2007, 45(10):1255-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26518/abstract-text/17968818/pubmed\" id=\"17968818\" target=\"_blank\">",
"        17968818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      King CT, Rogers PD, Cleary JD, et al, \"Antifungal Therapy During Pregnancy,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1998, 27(5):1151-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26518/abstract-text/9827262/pubmed\" id=\"9827262\" target=\"_blank\">",
"        9827262",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lister J, &ldquo;Amphotericin B Lipid Complex (Abelcet&reg;) in the Treatment of Invasive Mycoses: The North American Experience,&rdquo;",
"      <i>",
"       Eur J Haematol Suppl",
"      </i>",
"      , 1996, 57:18-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26518/abstract-text/8706812/pubmed\" id=\"8706812\" target=\"_blank\">",
"        8706812",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lyman CA and Walsh TJ, &ldquo;Systemically Administered Antifungal Agents. A Review of Their Clinical Pharmacology and Therapeutic Applications,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1992, 44(1):9-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26518/abstract-text/1379913/pubmed\" id=\"1379913\" target=\"_blank\">",
"        1379913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mactal-Haaf C, Hoffman M, and Kuchta A, \"Use of Anti-infective Agents During Lactation, Part 3: Antivirals, Antifungals, and Urinary Antiseptics,\"",
"      <i>",
"       J Hum Lact",
"      </i>",
"      , 2001, 17(2):160-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26518/abstract-text/11847833/pubmed\" id=\"11847833\" target=\"_blank\">",
"        11847833",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mora-Duarte J, Betts R, Rotstein C, et al, &ldquo;Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2002, 347(25):2020-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26518/abstract-text/12490683/pubmed\" id=\"12490683\" target=\"_blank\">",
"        12490683",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pappas PG, Kauffman CA, Andes D, et al, \"Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 48(5):503-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26518/abstract-text/19191635/pubmed\" id=\"19191635\" target=\"_blank\">",
"        19191635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patel R, &ldquo;Antifungal Agents. Part I. Amphotericin B Preparations and Flucytosine,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1998, 73(12):1205-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26518/abstract-text/9868423/pubmed\" id=\"9868423\" target=\"_blank\">",
"        9868423",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paterson DL, David K, Mrsic M, et al, &ldquo;Pre-medication Practices and Incidence of Infusion-related Reactions in Patients Receiving AMPHOTEC&reg;: Data from the Patients Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) Registry,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2008, 62(6):1392-1400.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26518/abstract-text/18812423/pubmed\" id=\"18812423\" target=\"_blank\">",
"        18812423",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perfect JR, Dismukes WE, Dromer F, et al, \"Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2010, 50(3):291-322.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26518/abstract-text/20047480/pubmed\" id=\"20047480\" target=\"_blank\">",
"        20047480",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prentice HG, Hann IM, Herbrecht R, et al, &ldquo;A Randomized Comparison of Liposomal Versus Conventional Amphotericin B for the Treatment of Pyrexia of Unknown Origin in Neutropenic Patients,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 1997, 98(3):711-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26518/abstract-text/9332329/pubmed\" id=\"9332329\" target=\"_blank\">",
"        9332329",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rex JH, Bennett JE, and Sugar AM, &ldquo;A Randomized Trial Comparing Fluconazole With Amphotericin B for the Treatment of Candidemia in Patients Without Neutropenia. Candidemia Study Group and the National Institute,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1994, 331(20):1325-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26518/abstract-text/7935701/pubmed\" id=\"7935701\" target=\"_blank\">",
"        7935701",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rex JH, Pappas PG, Karchmer AW, et al, &ldquo;A Randomized and Blinded Multicenter Trial of High-Dose Fluconazole Plus Placebo Versus Fluconazole Plus Amphotericin B as Therapy for Candidemia and Its Consequences in Nonneutropenic Subjects,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2003, 36(10):1221-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26518/abstract-text/12746765/pubmed\" id=\"12746765\" target=\"_blank\">",
"        12746765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Slain D, &ldquo;Lipid-Based Amphotericin B for the Treatment of Fungal Infections,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1999, 19(3):306-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26518/abstract-text/10221369/pubmed\" id=\"10221369\" target=\"_blank\">",
"        10221369",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wheat LJ, Freifeld AG, Kleiman MB, et al, \"Clinical Practice Guidelines for the Management of Patients With Histoplasmosis: 2007 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2007, 45(7):807-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26518/abstract-text/17806045/pubmed\" id=\"17806045\" target=\"_blank\">",
"        17806045",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8710 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3548BCC041-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_57_26518=[""].join("\n");
var outline_f25_57_26518=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134753\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134754\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134772\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134757\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134766\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134758\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134738\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134723\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134741\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134778\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134740\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134769\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134780\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134770\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134744\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134727\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298747\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134732\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134734\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13314096\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134762\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134747\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322987\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134736\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134748\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134726\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134743\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8710\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8710|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/59/38836?source=related_link\">",
"      Amphotericin B cholesteryl sulfate complex: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_57_26519="Nafcillin: Pediatric drug information";
var content_f25_57_26519=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nafcillin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"    see \"Nafcillin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/32/17924?source=see_link\">",
"    see \"Nafcillin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1048812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Penicillin (Antistaphylococcal)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     I.M., I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     For treatment of CNS infection, consider dosages at higher end of range.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     PNA 0-28 days and &lt;1200 g: 50 mg/kg/day in divided doses every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     PNA &lt;7 days:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1200-2000 g: 50 mg/kg/day in divided doses every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;2000 g: 75 mg/kg/day in divided doses every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     PNA &ge;7 days:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1200-2000 g: 75 mg/kg/day in divided doses every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;2000 g: 100-140 mg/kg/day in divided doses every 6 hours",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1048804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"      see \"Nafcillin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children: I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Mild to moderate infections:",
"     </b>",
"     50-100 mg/kg/day in divided doses every 6 hours; maximum daily dose: 4 g/",
"     <b>",
"      day",
"     </b>",
"     (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Severe infections:",
"     </b>",
"     100-150 mg/kg/day in divided doses every 4-6 hours; for life-threatening infection, doses up to 200 mg/kg have been used; maximum daily dose: 12 g/",
"     <b>",
"      day",
"     </b>",
"     (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Endocarditis, oxacillin/methicillin-susceptible staphylococci",
"     </b>",
"     (Baddour, 2005):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Native valve: I.V.: 200 mg/kg/day in divided doses every 4-6 hours for 6 weeks with gentamicin for the first 3-5 days of therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prosthetic valve: I.V.: 200 mg/kg/day in divided doses every 4-6 hours for &ge;6 weeks with rifampin (same duration as nafcillin) and with gentamicin for the first 2 weeks of therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Meningitis:",
"     </b>",
"     200 mg/kg/day in divided doses every 6 hours; maximum daily dose: 12 g/",
"     <b>",
"      day",
"     </b>",
"     (Tunkel, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Susceptible infections:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M.: 500 mg every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 500-2000 mg every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Endocarditis, oxacillin/methicillin-susceptible staphylococci:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Native valve: I.V.: 12 g/24 hours in 4-6 divided doses for 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prosthetic valve: I.V.: 12 g/24 hours in 6 divided dose for &ge;6 weeks (use with rifampin and gentamicin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Joint:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bursitis, septic: I.V.: 2 g every 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prosthetic: I.V.: 2 g every 4-6 hours with rifampin for 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Staphylococcus aureus",
"      </i>",
"      ; methicillin-susceptible infections including brain abscess, empyema, erysipelas, mastitis, myositis, orbital cellulitis, osteomyelitis, pneumonia, splenic abscess, toxic shock, urinary tract (perinephric abscess):",
"     </b>",
"     I.V.: 2 g every 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Not necessary unless renal impairment is in the setting of concomitant hepatic impairment; poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (eg, CVVHD)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     In patients with both hepatic and renal impairment, modification of dosage may be necessary; no data available.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F199154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic dextrose solution: 1 g (50 mL); 2 g (100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 1 g, 2 g, 10 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F199138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1048816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;display:inline\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Administer deep I.M. into a large muscle (ie, gluteus maximus) using a solution containing 250 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: May be administered by direct I.V. injection over 5-10 minutes by diluting dose in 15-30 mL of NS or SWI or by intermittent I.V. infusion over 30-60 minutes at a final concentration not to exceed 40 mg/mL; in fluid-restricted patients, a higher concentration may be used depending on the diluent (D",
"     <sub>",
"      5",
"     </sub>",
"     W: 71 mg/mL; NS: 64 mg/mL; SWI: 128 mg/mL) (Robinson, 1987)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F199204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 40 10% in dextrose, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     NS, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in peritoneal dialysis solution, TPN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, Aminosyn&reg; II, cyclosporine, enalaprilat, esmolol, famotidine, fluconazole, foscarnet, FreAmine&reg; III, heparin, hydromorphone, magnesium sulfate, morphine, oxytocin, phosphonoformate, propofol, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Caspofungin acetate, diltiazem, insulin (regular), labetalol, midazolam, verapamil.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Diltiazem, meperidine, vancomycin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1048808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Premixed infusions: Store in a freezer at &le;-20&deg;C (-4&deg;F). Thaw at room temperature or under refrigeration only. Thawed bags are stable for 21 days under refrigeration or 72 hours at room temperature. Do not refreeze.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vials: Store dry powder at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); reconstituted parenteral solution (250 mg/mL) is stable for 3 days at room temperature and 7 days when refrigerated or 12 weeks when frozen. For I.V. infusion in NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W, solution is stable for 24 hours at room temperature and 7 days when refrigerated. Incompatible with aminoglycosides.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1048815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of bacterial infections such as osteomyelitis, septicemia, endocarditis, and CNS infections due to susceptible penicillinase-producing strains of",
"     <i>",
"      Staphylococcus",
"     </i>",
"     (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F199203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Neurotoxicity (high doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal:",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, bone marrow depression, neutropenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Inflammation, pain, phlebitis, skin sloughing, swelling, and thrombophlebitis at the injection site; tissue necrosis with sloughing (SubQ extravasation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Interstitial nephritis (rare), renal tubular damage (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, hypersensitivity reactions (immediate and delayed; general incidence of 1% to 10% for penicillins), serum sickness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: ALT increased, AST increased, bilirubin increased, cholestatic hepatitis, diarrhea, drug-induced lupus erythematosus, fever, hypokalemia, itching, nausea, rash (including bullous skin eruptions), vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1048819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nafcillin, any component, or penicillins; premixed solutions: Hypersensitivity to corn or corn products",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1048803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Extravasation of I.V. infusions should be avoided; modification of dosage is necessary in patients with both severe renal and hepatic impairment; use with caution in patients with cephalosporin hypersensitivity",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1048802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serious and occasionally fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria); immediate treatment for anaphylactic reaction should be available during administration. In neonates, elimination rate is decreased due to immature hepatic and renal function; dosage adjustment is needed. Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F199195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F199147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Boceprevir.  Management: Avoid strong CYP3A4 inducers with boceprevir when possible, and closely monitor response to boceprevir if such a combination cannot be avoided. Carbamazepine, phenytoin, phenobarbital, rifampin, and St. John's wort are considered contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Nafcillin may increase the metabolism of Calcium Channel Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Nafcillin may increase the metabolism of Contraceptives (Estrogens).  Management: Use of an alternative, nonhormonal form of contraception during nafcillin therapy is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nafcillin may increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dienogest.  Management: Avoid use of dienogest for contraception when using medications that induce CYP3A4 and for at least 28 days after discontinuation of a CYP3A4 inducer.  An alternative form of contraception should be used during this time.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Penicillins may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Nafcillin may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F199150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5720663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Information specific to nafcillin use in pregnancy is limited. Maternal use of penicillins has generally not resulted in an increased risk of birth defects.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1048811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline and periodic CBC with differential, urinalysis, BUN, serum creatinine, AST, and ALT; initial culture and susceptibility test; observe for signs and symptoms of anaphylaxis during first dose and I.V. site for extravasation",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1048801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with bacterial cell wall synthesis during active multiplication by binding to one or more of the penicillin-binding proteins; inhibits the final transpeptidation step of peptidoglycan synthesis causing cell wall death and resultant bactericidal activity against susceptible bacteria",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1048818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes into bile, synovial, pleural, ascitic, and pericardial fluids and into bone and liver; CSF penetration is poor unless meninges are inflamed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neonates: 0.24-0.53 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 0.85-0.91 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 0.57-1.55 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~90%; primarily albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic; undergoes enterohepatic recirculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates and Infants &lt;9 weeks:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;3 weeks: 2.2-5.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     4-9 weeks: 1.2-2.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children 1 month to 14 years: 0.75-1.9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Normal renal and hepatic function: 0.5-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: I.M.: Within 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily feces; urine (10% to 30% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not dialyzable (0% to 5%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F4796759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/32/17924?source=see_link\">",
"      see \"Nafcillin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report any redness, swelling, burning, or pain at injection site; report any difficulty in swallowing or respiration.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1048820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium content of 1 g injection: 3.33 mEq",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     In a study of pediatric patients (5-19 years) receiving outpatient nafcillin for &gt;3 weeks, significantly less rash was reported in the nafcillin group compared  to oxacillin (Maraqa, 2002). Solutions for ambulatory I.V. infusion reservoirs (eg, &gt;24-hour supply) may be subject to inadvertent exposure to temperatures higher than recommended due to heat radiation from patient's skin; lower concentrations of preparation may be needed to prevent precipitation of solution in some circumstances (Chan, 2005)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Baddour LM, Wilson WR, Bayer AS, et al, \"Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2005, 111(23):e394-434.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26519/abstract-text/15956145/pubmed\" id=\"15956145\" target=\"_blank\">",
"        15956145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Banner W Jr, Gooch WM 3d, Burckart G, et al, \"Pharmacokinetics of Nafcillin in Infants With Low Birth Weights,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1980, 17(4):691-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26519/abstract-text/7396459/pubmed\" id=\"7396459\" target=\"_blank\">",
"        7396459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chan V, \"Influence of Temperature and Drug Concentration on Nafcillin Precipitation,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2005, 62(13):1347-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26519/abstract-text/15972371/pubmed\" id=\"15972371\" target=\"_blank\">",
"        15972371",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dahlgren AF, \"Adverse Drug Reactions in Home Care Patients Receiving Nafcillin or Oxacillin,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1997, 54(10):1176-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26519/abstract-text/9161625/pubmed\" id=\"9161625\" target=\"_blank\">",
"        9161625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Faden D and Faden HS, \"The High Rate of Adverse Drug Events in Children Receiving Prolonged Outpatient Parenteral Antibiotic Therapy for Osteomyelitis,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2009, 28(6):539-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26519/abstract-text/19483522/pubmed\" id=\"19483522\" target=\"_blank\">",
"        19483522",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maraqa NF, Gomez MM, Rathore MH, et al, \"Higher Occurrence of Hepatotoxicity and Rash in Patients Treated With Oxacillin, Compared With Those Treated With Nafcillin and Other Commonly Used Antimicrobials,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2002, 34(1):50-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26519/abstract-text/11731945/pubmed\" id=\"11731945\" target=\"_blank\">",
"        11731945",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robinson DC, Cookson TL, and Grisafe JA, \"Concentration Guidelines for Parenteral Antibiotics in Fluid-Restricted Patients,\"",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1987, 21(12):985-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26519/abstract-text/3428165/pubmed\" id=\"3428165\" target=\"_blank\">",
"        3428165",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tunkel AR, Hartman BJ, Kaplan SL, et al, \"Practice Guidelines for the Management of Bacterial Meningitis,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2004, 39(9):1267-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26519/abstract-text/15494903/pubmed\" id=\"15494903\" target=\"_blank\">",
"        15494903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zenk KE, Dungy CL, and Greene CR, \"Nafcillin Extravasation Injury: Use of Hyaluronidase as an Antidote,\"",
"      <i>",
"       Am J Dis Child",
"      </i>",
"      , 1981, 135(12):1113-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/57/26519/abstract-text/7315807/pubmed\" id=\"7315807\" target=\"_blank\">",
"        7315807",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12626 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-2332FC6495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_57_26519=[""].join("\n");
var outline_f25_57_26519=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048812\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443894\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048804\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199154\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199138\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048816\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199204\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048808\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048815\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199203\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048819\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048803\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048802\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199195\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199147\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199150\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5720663\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048811\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048801\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048818\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4796759\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048820\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12626\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12626|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=related_link\">",
"      Nafcillin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/32/17924?source=related_link\">",
"      Nafcillin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_57_26520="Diagnosis of hyperthyroidism";
var content_f25_57_26520=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of hyperthyroidism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/57/26520/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/57/26520/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/57/26520/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/57/26520/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/57/26520/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/57/26520/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/57/26520/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of hyperthyroidism is usually evident in patients with unequivocal clinical and biochemical manifestations of the disease. Other patients have fewer and less obvious clinical signs, but definite biochemical hyperthyroidism. Still others have little or no clinical hyperthyroidism and their only biochemical abnormality is a low serum thyrotropin (TSH) concentration, a disorder called subclinical hyperthyroidism.",
"   </p>",
"   <p>",
"    Following a brief discussion of the clinical manifestations of hyperthyroidism, the diagnosis and evaluation of patients with hyperthyroidism will be presented here. An overview of the clinical manifestations of hyperthyroidism, disorders that cause hyperthyroidism, the diagnosis of hyperthyroidism during pregnancy, and subclinical hyperthyroidism are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=see_link\">",
"     \"Disorders that cause hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12871?source=see_link\">",
"     \"Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=see_link\">",
"     \"Subclinical hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25975024\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Overt hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with overt hyperthyroidism have a dramatic constellation of symptoms. These symptoms characteristically include anxiety, emotional lability, weakness, tremor, palpitations, heat intolerance, increased perspiration, and weight loss despite a normal or increased appetite [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26520/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the combination of weight loss and increased appetite is a characteristic finding, some patients gain weight, in particular younger patients, due to excessive appetite stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26520/abstract/1\">",
"     1",
"    </a>",
"    ]. Other symptoms that may be present include hyperdefecation (not diarrhea), urinary frequency, oligomenorrhea or amenorrhea in women, and gynecomastia and erectile dysfunction in men [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26520/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Milder symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mild hyperthyroidism and older patients often have symptoms that are referable to one or only a few organ systems [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26520/abstract/5\">",
"     5",
"    </a>",
"    ]. Isolated symptoms and signs that should lead to evaluation for hyperthyroidism in patients of any age include unexplained weight loss, new onset atrial fibrillation, myopathy, menstrual disorders, and gynecomastia.",
"   </p>",
"   <p>",
"    Other conditions that should suggest the possibility of hyperthyroidism include osteoporosis, hypercalcemia, heart failure, premature atrial contractions, shortness of breath, and a deterioration in glycemic control in patients with previously diagnosed diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Older patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In older patients, cardiopulmonary symptoms such as tachycardia (or atrial fibrillation), dyspnea on exertion, and edema may predominate [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26520/abstract/1,6-8\">",
"     1,6-8",
"    </a>",
"    ]. They also tend to have more weight loss and less of an increase in appetite [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26520/abstract/1\">",
"     1",
"    </a>",
"    ]. The most dramatic example of this phenomenon is \"apathetic thyrotoxicosis,\" in which elderly patients have no symptoms except for weakness and asthenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\", section on 'Geriatric hyperthyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subclinical hyperthyroidism, defined as normal serum levels of free T4 and T3 with a suppressed TSH level, is associated with a threefold increase in the risk of atrial fibrillation in older persons (",
"    <a class=\"graphic graphic_figure graphicRef55024 \" href=\"UTD.htm?19/0/19469\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=see_link&amp;anchor=H9#H9\">",
"     \"Subclinical hyperthyroidism\", section on 'Atrial fibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination may be notable for hyperactivity and rapid speech. Many patients have stare (lid retraction) and lid lag, representing sympathetic hyperactivity. The skin is typically warm and moist, and the hair may be thin and fine. Tachycardia is common, the pulse is irregularly irregular in patients with atrial fibrillation, systolic hypertension may be present, and the precordium is often hyperdynamic [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26520/abstract/6\">",
"     6",
"    </a>",
"    ]. Tremor, proximal muscle weakness, and hyperreflexia are other frequent findings.",
"   </p>",
"   <p>",
"    Exophthalmos, periorbital and conjunctival edema, limitation of eye movement, and infiltrative dermopathy (pretibial myxedema) occur only in patients with Graves' disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3432?source=see_link\">",
"     \"Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1828?source=see_link\">",
"     \"Pretibial myxedema in autoimmune thyroid disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Thyroid size",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence and size of a goiter depends upon the cause of the hyperthyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=see_link\">",
"     \"Disorders that cause hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thyroid enlargement ranges from minimal to massive in patients with Graves' disease or toxic multinodular goiter. A nonpalpable thyroid occurs commonly in elderly patients with Graves' disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=see_link&amp;anchor=H6#H6\">",
"       \"Disorders that cause hyperthyroidism\", section on 'Toxic adenoma and toxic multinodular goiter'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link&amp;anchor=H15#H15\">",
"       \"Overview of the clinical manifestations of hyperthyroidism in adults\", section on 'Geriatric hyperthyroidism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with painless (silent or lymphocytic) thyroiditis may have no, minimal, or modest thyroid enlargement. The absence of any thyroid enlargement should also suggest exogenous hyperthyroidism or struma ovarii. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4165?source=see_link\">",
"       \"Exogenous hyperthyroidism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13799?source=see_link\">",
"       \"Struma ovarii\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A single palpable nodule raises the possibility of an autonomously functioning thyroid adenoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=see_link&amp;anchor=H6#H6\">",
"       \"Disorders that cause hyperthyroidism\", section on 'Toxic adenoma and toxic multinodular goiter'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The thyroid is painful and tender in subacute (granulomatous) thyroiditis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/23/1399?source=see_link\">",
"       \"Subacute thyroiditis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16194856\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16195540\">",
"    <span class=\"h3\">",
"     Thyroid function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with primary hyperthyroidism have a low TSH. The serum TSH concentration alone cannot determine the degree of biochemical hyperthyroidism; serum free thyroxine (T4) and triiodothyronine (T3) are required to provide this information. However, in laboratories utilizing serum TSH assays with detection limits of 0.01",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    (third generation), most patients with overt hyperthyroidism have values &lt;0.05",
"    <span class=\"nowrap\">",
"     mU/L.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=see_link\">",
"     \"Laboratory assessment of thyroid function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients with overt hyperthyroidism have high free T4 and T3 concentrations. In some patients, however, only the serum T3 or serum T4 is elevated. In patients with subclinical hyperthyroidism, TSH is below normal (but usually &gt;0.05",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    and serum free T4, T3, and free T3 are normal. (See",
"    <a class=\"local\" href=\"#H25975064\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16195560\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hyperthyroidism may have other nonspecific laboratory findings. As an example, patients with hyperthyroidism tend to have low serum total, low-density (LDL), and high-density lipoprotein (HDL) cholesterol concentrations, which increase after treatment. In addition, the red blood cell mass may be increased in hyperthyroidism, but the plasma volume is increased more, resulting in a normochromic, normocytic anemia. Serum alkaline phosphatase and osteocalcin concentrations may be high, indicative of increased bone turnover. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\", section on 'Metabolic / endocrine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\", section on 'Hematologic'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\", section on 'Bone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25975064\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of hyperthyroidism is based upon thyroid function tests. In patients in whom there is a clinical suspicion of hyperthyroidism, the best initial test is serum TSH. If the value is normal, the patient is very unlikely to have primary hyperthyroidism. Many laboratories have instituted algorithms in which serum free T4 and T3 are automatically measured if a low serum TSH value is obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26520/abstract/9\">",
"     9",
"    </a>",
"    ]. If a laboratory is unable to add these determinations to a low TSH value, and it will be inconvenient for the patient to return for follow-up testing, it is reasonable to order serum TSH, free T4, and T3 as initial tests in patients in whom the clinical suspicion of hyperthyroidism is high. In addition, if hyperthyroidism is strongly suspected despite a normal or elevated serum TSH value, serum free T4 and T3 should be measured. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=see_link\">",
"     \"Laboratory assessment of thyroid function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16195383\">",
"    <span class=\"h2\">",
"     Overt hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of overt hyperthyroidism is usually straightforward. Except for laboratory error, all patients with low serum TSH and high free T4",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    T3 concentrations have primary hyperthyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16194933\">",
"    <span class=\"h2\">",
"     T3-toxicosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with overt hyperthyroidism caused by Graves' disease or nodular goiter have greater increases in serum T3 than in serum T4, due both to a disproportionate increase in thyroidal T3 secretion and increased extrathyroidal conversion of T4 to T3 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26520/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with T3-toxicosis by definition have symptoms and signs of hyperthyroidism but only high serum T3 (and low TSH) concentrations. An occasional patient will have normal serum T3 and free T4 levels, but will have an elevated serum free T3 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26520/abstract/11\">",
"     11",
"    </a>",
"    ]. This pattern of test results tends to occur early in the course of hyperthyroidism, a time at which most patients have relatively few symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16194990\">",
"    <span class=\"h2\">",
"     T4-toxicosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pattern of low TSH, high serum free T4, and normal T3 concentrations is called T4-toxicosis. It may be found in patients with hyperthyroidism who have a concurrent nonthyroidal illness that decreases extrathyroidal conversion of T4 to T3 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26520/abstract/12\">",
"     12",
"    </a>",
"    ]. Despite the nonthyroidal illness, these patients remain hyperthyroid and their serum TSH concentrations are low; with recovery from the nonthyroidal illness, serum T3 concentrations rise unless the hyperthyroidism is recognized and treated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=see_link\">",
"     \"Thyroid function in nonthyroidal illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    inhibits extrathyroidal conversion of T4 to T3 in all patients. Thus, patients with amiodarone-induced hyperthyroidism may also have T4-hyperthyroidism (or at least have serum T3 concentrations that are not as elevated as in patients with Graves' hyperthyroidism). This pattern is present whether the hyperthyroidism is caused by amiodarone-induced thyroiditis or iodide excess [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26520/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25065?source=see_link\">",
"     \"Amiodarone and thyroid dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16195081\">",
"    <span class=\"h2\">",
"     Subclinical hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of sensitive assays for thyrotropin (TSH) resulted in the identification of patients who have low serum TSH concentrations (&lt;0.5",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    but normal serum free thyroxine (T4), triiodothyronine (T3), and free T3 concentrations, a constellation of biochemical findings defined as subclinical hyperthyroidism. Most of these patients have no clinical manifestations of hyperthyroidism, and those symptoms that are present are mild and nonspecific. Many patients have a multinodular goiter with autonomy (toxic nodular goiter) or mild Graves' disease. Most patients are detected through routine screening of thyroid function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=see_link\">",
"     \"Subclinical hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16195327\">",
"    <span class=\"h2\">",
"     TSH-induced hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;TSH-induced hyperthyroidism is a very rare cause of overt hyperthyroidism, due to either a TSH-secreting pituitary adenoma or partial resistance to the feedback effect of T4 and T3 on TSH secretion (due to defects in the T3-nuclear receptor) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26520/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. These patients have normal or high serum TSH despite high free T4 and T3 concentrations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/20/327?source=see_link\">",
"     \"Thyrotropin (TSH)-secreting pituitary adenomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/37/1626?source=see_link\">",
"     \"Reduced sensitivity to thyroid hormone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1437846\">",
"    <span class=\"h2\">",
"     Critically ill patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, patients with hyperthyroidism who are critically ill due to a nonthyroidal illness have normal serum total T4 and normal or even low T3 concentrations. Serum T4 and even free T4 concentrations may be normal because of decreased protein-binding of T4, caused by either low serum concentrations of thyroxine-binding globulin, displacement of T4 from binding proteins by endogenous metabolites or drugs, and other factors. Similar results (low-normal serum T4, normal or low serum T3, and low serum TSH concentrations) are found in euthyroid patients in intensive care units. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=see_link\">",
"     \"Thyroid function in nonthyroidal illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since critically ill hyperthyroid patients and many euthyroid critically ill patients have low serum TSH concentrations, identification of those that are hyperthyroid may be difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26520/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The nonthyroidal illness may overshadow or mimic hyperthyroidism (by causing tachycardia, tremor, weakness). Since many critically ill patients have low serum T4 and T3 concentrations, a serum T4 value well within the normal range suggests the possible presence of hyperthyroidism. The diagnosis is further supported by very low serum TSH values, eg, less than 0.01",
"    <span class=\"nowrap\">",
"     mU/L.",
"    </span>",
"    In contrast, detectable but subnormal TSH values (eg, TSH 0.1 to 0.4",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    in an assay with a detection limit of 0.01",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    are more consistent with nonthyroidal illness alone [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26520/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In critically ill patients with suspected hyperthyroidism (TSH &lt;0.01",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    and normal serum T4), antithyroid drug therapy should be instituted, with a plan for reassessment after recovery from the nonthyroidal illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16194820\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several situations in which the diagnosis of hyperthyroidism may be missed or incorrectly suspected:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Euthyroid hyperthyroxinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of hyperthyroidism may be incorrectly suspected in patients who have one of several abnormalities in serum thyroid hormone-binding proteins that result in high serum total (and sometimes free) T4 concentrations and normal (or slightly high) T3 concentrations. These patients have normal TSH concentrations and are euthyroid (euthyroid hyperthyroxinemia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/53/856?source=see_link\">",
"     \"Euthyroid hyperthyroxinemia and hypothyroxinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Low serum TSH without hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are other causes of the combination of low serum TSH and normal free T4 and T3 concentrations other than subclinical hyperthyroidism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Central hypothyroidism &mdash; Some patients with central hypothyroidism have low serum TSH and normal (but usually low-normal) free T4 and T3 concentrations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"       \"Diagnosis of and screening for hypothyroidism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=see_link\">",
"       \"Central hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonthyroidal illness &mdash; Euthyroid patients with nonthyroidal illness, especially those receiving high-dose glucocorticoids or dopamine, may have low serum TSH but low or low-normal free T4 and very low serum T3 concentrations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=see_link\">",
"       \"Thyroid function in nonthyroidal illness\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recovery from hyperthyroidism &mdash; Serum TSH concentrations may remain low for up to several months after normalization of serum T4 and T3 concentrations in patients treated for hyperthyroidism or recovering from hyperthyroidism caused by thyroiditis.",
"     </li>",
"     <li>",
"      The \"physiologic\" lowering of serum TSH in pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=see_link&amp;anchor=H994022#H994022\">",
"       \"Overview of thyroid disease in pregnancy\", section on 'hCG and thyroid function'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An altered set point of the hypothalamic-pituitary-thyroid axis in some otherwise healthy elderly persons [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26520/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In hospitalized patients with detectable but subnormal serum TSH concentrations and normal free T4 and T3 concentrations, a practical approach is to reevaluate the patient in four to eight weeks. By that time, it should be apparent whether the low serum TSH value was due to nonthyroidal illness or true thyroid dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=see_link\">",
"     \"Thyroid function in nonthyroidal illness\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=see_link&amp;anchor=H14#H14\">",
"     \"Subclinical hyperthyroidism\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DETERMINING THE ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of hyperthyroidism has been established, the cause of the hyperthyroidism should be determined. Although the pattern of abnormal thyroid tests or certain findings on physical examination (eg, ophthalmopathy and diffuse goiter) may suggest a specific diagnosis, many patients require a radioiodine uptake for definitive diagnosis. In patients with newly diagnosed hyperthyroidism (suppressed TSH, elevated free T4",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    T3) and without obvious clinical manifestations of Graves&rsquo; disease (eg, ophthalmopathy), we obtain a 24-hour radioiodine uptake and scan (",
"    <a class=\"graphic graphic_table graphicRef76972 \" href=\"UTD.htm?31/45/32476\">",
"     table 1",
"    </a>",
"    ). Measurement of thyrotropin receptor antibodies is a less precise alternative for diagnosing Graves&rsquo; hyperthyroidism (sensitivity 95 percent), since it may not be elevated in mild disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26520/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. However, in such situations where the clinical diagnosis is uncertain and radionuclide imaging is contraindicated, thyrotropin (TSH) receptor antibodies (TRAb), using a second-generation thyrotropin-binding inhibitory immunoglobulin (TBII) assay, should be measured. (See",
"    <a class=\"local\" href=\"#H143073065\">",
"     'Other tests'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61539983\">",
"    <span class=\"h2\">",
"     Thyroid tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sometimes the pattern of thyroid function test abnormalities suggests a specific diagnosis. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If TSH is low, and serum T3, but not free T4 concentration is high, the patient most likely has Graves' disease or an autonomously functioning thyroid adenoma. This pattern is more common in regions of marginal iodine intake than in the United States. Another possibility is exogenous T3 ingestion. T3-hyperthyroidism can also be seen in patients taking antithyroid drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26520/abstract/22\">",
"       22",
"      </a>",
"      ]. A radioiodine scan can differentiate between Graves&rsquo; disease or autonomy and exogenous intake of T3. (See",
"      <a class=\"local\" href=\"#H25975118\">",
"       'Radioiodine uptake'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      If TSH is low, free T4 is high, and T3 is normal, the patient may have hyperthyroidism with concurrent nonthyroidal illness,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      induced thyroid dysfunction, or exogenous T4 ingestion. Patients who ingest exogenous thyroxine may have high serum T4 and T3 concentrations, but the",
"      <span class=\"nowrap\">",
"       T3/T4",
"      </span>",
"      ratio is lower than that in most patients with Graves&rsquo; hyperthyroidism and toxic adenoma(s) whose",
"      <span class=\"nowrap\">",
"       T3/T4",
"      </span>",
"      ratio usually exceeds 20",
"      <span class=\"nowrap\">",
"       (ng/mcg)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26520/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=see_link\">",
"       \"Thyroid function in nonthyroidal illness\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25065?source=see_link\">",
"       \"Amiodarone and thyroid dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If free T4 and T3 are elevated, and serum TSH is normal or elevated, serum alpha subunit and a pituitary MRI should be obtained to assess the possibility of a TSH-producing pituitary tumor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/20/327?source=see_link\">",
"       \"Thyrotropin (TSH)-secreting pituitary adenomas\"",
"      </a>",
"      .) Patients with resistance to thyroid hormone have variable degrees of end-organ evidence of hyperthyroidism and a family history of \"hyperthyroidism\" or genetic abnormalities in the T3 receptor; commercial assays for genetic testing for thyroid hormone resistance are now available. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/37/1626?source=see_link\">",
"       \"Reduced sensitivity to thyroid hormone\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The various causes of hyperthyroidism and the tests used to identify them are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=see_link\">",
"     \"Disorders that cause hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24694?source=see_link\">",
"     \"Painless thyroiditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/23/1399?source=see_link\">",
"     \"Subacute thyroiditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4165?source=see_link\">",
"     \"Exogenous hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32185?source=see_link\">",
"     \"Diagnostic approach to and treatment of goiter in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25975118\">",
"    <span class=\"h2\">",
"     Radioiodine uptake",
"    </span>",
"    &nbsp;&mdash;&nbsp;From a pathogenetic viewpoint, hyperthyroidism results from two different mechanisms that can be distinguished by the findings on the 24-hour radioiodine uptake (",
"    <a class=\"graphic graphic_table graphicRef76972 \" href=\"UTD.htm?31/45/32476\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperthyroidism with a",
"      <strong>",
"       high",
"      </strong>",
"      (or normal) radioiodine uptake indicates de novo synthesis of hormone.",
"     </li>",
"     <li>",
"      Hyperthyroidism with a",
"      <strong>",
"       low",
"      </strong>",
"      (nearly absent) radioiodine uptake indicates either inflammation and destruction of thyroid tissue with release of preformed hormone into the circulation or an extrathyroidal source of thyroid hormone, such as in patients with factitious thyrotoxicosis and in patients with struma ovarii, where the functioning thyroid tissue is in the pelvis rather than the neck. Patients who have been exposed to large amounts of iodine (eg, intravenous radiographic contrast,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ) may also have a misleading low radioiodine uptake, although a nearly absent level of uptake after iodine exposure is common only with amiodarone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A radioiodine uptake and scan may be indeterminate in a patient with subclinical hyperthyroidism due to an autonomous nodule. A suppression scan may better demonstrate an area of focal autonomy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67109 \" href=\"UTD.htm?27/62/28655\">",
"     image 1",
"    </a>",
"    ). Suppression scans are reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\", section on 'Thyroid scintigraphy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H143073065\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy and breastfeeding are absolute contraindications to radionuclide imaging. In such situations where the clinical diagnosis is uncertain and radionuclide imaging is contraindicated or unavailable, thyrotropin (TSH) receptor antibodies (TRAb), using a second-generation thyrotropin-binding inhibitory immunoglobulin (TBII) assay, should be measured (note that commercial labs tend to call these assays TBII in the United States, but they are referred to as TRAb in Europe). In one study evaluating a second-generation TBII assay, the sensitivity and specificity for diagnosing Graves&rsquo;s disease were 95 and 99 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26520/abstract/21\">",
"     21",
"    </a>",
"    ]. Therefore, in the presence of TSH receptor antibodies, it is reasonable to assume the diagnosis of Graves' hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26520/abstract/20,24,25\">",
"     20,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other measurements that help differentiate Graves&rsquo; hyperthyroidism from destruction-induced hyperthyroidism when a radioiodine uptake is contraindicated include a serum T3 to T4 ratio &gt;20 (in standard units",
"    <span class=\"nowrap\">",
"     ng/mcg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26520/abstract/23\">",
"     23",
"    </a>",
"    ] and a serum free T3 to free T4 ratio &gt;0.3 (SI units) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26520/abstract/26\">",
"     26",
"    </a>",
"    ]. Additionally, assessment of quantitative thyroid blood flow by ultrasonography may be helpful to differentiate Graves' hyperthyroidism from painless thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26520/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12871?source=see_link&amp;anchor=H12186870#H12186870\">",
"     \"Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes\", section on 'Establishing the cause'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=see_link&amp;anchor=H29#H29\">",
"     \"Overview of the clinical utility of ultrasonography in thyroid disease\", section on 'Autoimmune thyroid disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=see_link\">",
"       \"Patient information: Antithyroid drugs (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with hyperthyroidism may have symptoms that include anxiety, emotional lability, weakness, tremor, palpitations, heat intolerance, increased perspiration, and weight loss despite a normal or increased appetite. The physical examination may be notable for hyperactivity and rapid speech. The presence and size of a goiter depends upon the cause of the hyperthyroidism. Exophthalmos, periorbital and conjunctival edema, limitation of eye movement, and infiltrative dermopathy (pretibial myxedema) occur only in patients with Graves' disease. (See",
"      <a class=\"local\" href=\"#H25975024\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with primary hyperthyroidism have a low TSH. Many patients with overt hyperthyroidism have high free T4 and T3 concentrations. In some patients, however, only the serum T3 or serum T4 is elevated. In patients with subclinical hyperthyroidism, TSH is below normal (but usually &gt;0.05",
"      <span class=\"nowrap\">",
"       mU/L)",
"      </span>",
"      and serum free T4, T3, and free T3 are normal. Both overt and subclinical hyperthyroidism are biochemical definitions since hyperthyroid symptoms are non-specific and may be present in patients with subclinical disease, and absent in those with overt disease, especially the elderly. (See",
"      <a class=\"local\" href=\"#H16195540\">",
"       'Thyroid function tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients in whom hyperthyroidism is suspected, serum TSH is the best initial test. If subnormal, serum free T4 and T3 concentrations are run by most laboratories. If serum free T4 and T3 are not automatically measured when a low serum TSH value is obtained, but the index of suspicion for hyperthyroidism is high, a free T4 and T3 should be ordered with the initial TSH measurement. (See",
"      <a class=\"local\" href=\"#H25975064\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If serum TSH is low, and free T4 and T3 are high, the diagnosis of hyperthyroidism is confirmed. If the diagnosis of Graves&rsquo; disease is not clinically apparent (eg, the presence of ophthalmopathy and a diffuse goiter), a 24-hour thyroid radioiodine uptake and scan should be done to differentiate Graves' hyperthyroidism from other causes (",
"      <a class=\"graphic graphic_table graphicRef76972 \" href=\"UTD.htm?31/45/32476\">",
"       table 1",
"      </a>",
"      ). If radionuclide imaging is contraindicated (pregnancy, breastfeeding), and the diagnosis of Graves&rsquo; is uncertain, thyrotropin (TSH) receptor antibodies (TRAb), using a second-generation thyrotropin-binding inhibitory immunoglobulin (TBII) assay, should be measured. (See",
"      <a class=\"local\" href=\"#H25975064\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Determining the etiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25975118\">",
"       'Radioiodine uptake'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If TSH is low, and serum T3, but not free T4 concentration is high, the patient most likely has Graves&rsquo; disease or an autonomously functioning thyroid adenoma. However, the possibility of exogenous T3 ingestion should also be considered. (See",
"      <a class=\"local\" href=\"#H16194933\">",
"       'T3-toxicosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Determining the etiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4165?source=see_link\">",
"       \"Exogenous hyperthyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The pattern of low TSH, high serum free T4, and normal T3 concentrations suggests hyperthyroidism with concurrent nonthyroidal illness,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      therapy, or exogenous T4 ingestion. (See",
"      <a class=\"local\" href=\"#H16194990\">",
"       'T4-toxicosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Determining the etiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=see_link\">",
"       \"Thyroid function in nonthyroidal illness\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25065?source=see_link\">",
"       \"Amiodarone and thyroid dysfunction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4165?source=see_link\">",
"       \"Exogenous hyperthyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If free T4 and T3 are high, but TSH is normal or high, a pituitary MRI should be done to look for a pituitary mass (TSH-secreting adenoma). If there is no pituitary mass, but there is end-organ evidence of hyperthyroidism, a careful family pedigree should be obtained as well as genetic testing for the possibility of thyroid hormone resistance. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Determining the etiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/20/327?source=see_link\">",
"       \"Thyrotropin (TSH)-secreting pituitary adenomas\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/37/1626?source=see_link\">",
"       \"Reduced sensitivity to thyroid hormone\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients without overt signs of hyperthyroidism in the setting of a low serum TSH and normal free T4 and T3 concentrations most likely have subclinical hyperthyroidism. Other possibilities include central hypothyroidism, nonthyroidal illness, recovery from hyperthyroidism, early pregnancy, or possibly a normal finding in some healthy older persons. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=see_link\">",
"       \"Subclinical hyperthyroidism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=see_link\">",
"       \"Central hypothyroidism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=see_link\">",
"       \"Thyroid function in nonthyroidal illness\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/1\">",
"      Nordyke RA, Gilbert FI Jr, Harada AS. Graves' disease. Influence of age on clinical findings. Arch Intern Med 1988; 148:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/2\">",
"      Trzepacz PT, Klein I, Roberts M, et al. Graves' disease: an analysis of thyroid hormone levels and hyperthyroid signs and symptoms. Am J Med 1989; 87:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/3\">",
"      Krassas GE, Pontikides N, Kaltsas T, et al. Menstrual disturbances in thyrotoxicosis. Clin Endocrinol (Oxf) 1994; 40:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/4\">",
"      Kidd GS, Glass AR, Vigersky RA. The hypothalamic-pituitary-testicular axis in thyrotoxicosis. J Clin Endocrinol Metab 1979; 48:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/5\">",
"      Trivalle C, Doucet J, Chassagne P, et al. Differences in the signs and symptoms of hyperthyroidism in older and younger patients. J Am Geriatr Soc 1996; 44:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/6\">",
"      Woeber KA. Thyrotoxicosis and the heart. N Engl J Med 1992; 327:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/7\">",
"      Ayres J, Rees J, Clark TJ, Maisey MN. Thyrotoxicosis and dyspnoea. Clin Endocrinol (Oxf) 1982; 16:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/8\">",
"      Boelaert K, Torlinska B, Holder RL, Franklyn JA. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J Clin Endocrinol Metab 2010; 95:2715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/9\">",
"      Davey RX, Clarke MI, Webster AR. Thyroid function testing based on assay of thyroid-stimulating hormone: assessing an algorithm's reliability. Med J Aust 1996; 164:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/10\">",
"      Laurberg P, Vestergaard H, Nielsen S, et al. Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. J Clin Endocrinol Metab 2007; 92:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/11\">",
"      Figge J, Leinung M, Goodman AD, et al. The clinical evaluation of patients with subclinical hyperthyroidism and free triiodothyronine (free T3) toxicosis. Am J Med 1994; 96:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/12\">",
"      Caplan RH, Pagliara AS, Wickus G. Thyroxine toxicosis. A common variant of hyperthyroidism. JAMA 1980; 244:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/13\">",
"      Bambini G, Aghini-Lombardi F, Rosner W, et al. Serum sex hormone-binding globulin in amiodarone-treated patients. A marker for tissue thyrotoxicosis. Arch Intern Med 1987; 147:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/14\">",
"      Wynne AG, Gharib H, Scheithauer BW, et al. Hyperthyroidism due to inappropriate secretion of thyrotropin in 10 patients. Am J Med 1992; 92:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/15\">",
"      Beck-Peccoz P, Chatterjee VK. The variable clinical phenotype in thyroid hormone resistance syndrome. Thyroid 1994; 4:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/16\">",
"      Spencer C, Eigen A, Shen D, et al. Specificity of sensitive assays of thyrotropin (TSH) used to screen for thyroid disease in hospitalized patients. Clin Chem 1987; 33:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/17\">",
"      Franklyn JA, Black EG, Betteridge J, Sheppard MC. Comparison of second and third generation methods for measurement of serum thyrotropin in patients with overt hyperthyroidism, patients receiving thyroxine therapy, and those with nonthyroidal illness. J Clin Endocrinol Metab 1994; 78:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/18\">",
"      Lewis GF, Alessi CA, Imperial JG, Refetoff S. Low serum free thyroxine index in ambulating elderly is due to a resetting of the threshold of thyrotropin feedback suppression. J Clin Endocrinol Metab 1991; 73:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/19\">",
"      Mariotti S, Barbesino G, Caturegli P, et al. Complex alteration of thyroid function in healthy centenarians. J Clin Endocrinol Metab 1993; 77:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/20\">",
"      Lytton SD, Kahaly GJ. Bioassays for TSH-receptor autoantibodies: an update. Autoimmun Rev 2010; 10:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/21\">",
"      Pedersen IB, Knudsen N, Perrild H, et al. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: a comparison of two competitive binding assays. Clin Endocrinol (Oxf) 2001; 55:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/22\">",
"      Chen JJ, Ladenson PW. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease. J Clin Endocrinol Metab 1986; 63:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/23\">",
"      Amino N, Yabu Y, Miki T, et al. Serum ratio of triiodothyronine to thyroxine, and thyroxine-binding globulin and calcitonin concentrations in Graves' disease and destruction-induced thyrotoxicosis. J Clin Endocrinol Metab 1981; 53:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/24\">",
"      Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011; 21:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/25\">",
"      Vos XG, Smit N, Endert E, et al. Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves' hyperthyroidism: a prospective study. Clin Endocrinol (Oxf) 2008; 69:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/26\">",
"      Izumi Y, Hidaka Y, Tada H, et al. Simple and practical parameters for differentiation between destruction-induced thyrotoxicosis and Graves' thyrotoxicosis. Clin Endocrinol (Oxf) 2002; 57:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26520/abstract/27\">",
"      Ota H, Amino N, Morita S, et al. Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves' disease. Clin Endocrinol (Oxf) 2007; 67:41.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7847 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C7EAEF3114-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_57_26520=[""].join("\n");
var outline_f25_57_26520=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25975024\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Overt hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Milder symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Older patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Thyroid size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16194856\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16195540\">",
"      - Thyroid function tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16195560\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25975064\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16195383\">",
"      Overt hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16194933\">",
"      T3-toxicosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16194990\">",
"      T4-toxicosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16195081\">",
"      Subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16195327\">",
"      TSH-induced hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1437846\">",
"      Critically ill patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16194820\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Euthyroid hyperthyroxinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Low serum TSH without hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DETERMINING THE ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61539983\">",
"      Thyroid tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25975118\">",
"      Radioiodine uptake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H143073065\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7847\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7847|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/62/28655\" title=\"diagnostic image 1\">",
"      Thyroid suppression scan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7847|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/0/19469\" title=\"figure 1\">",
"      Increased incidence of AF in subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7847|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/45/32476\" title=\"table 1\">",
"      Causes of hyperthyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25065?source=related_link\">",
"      Amiodarone and thyroid dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=related_link\">",
"      Central hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32185?source=related_link\">",
"      Diagnostic approach to and treatment of goiter in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=related_link\">",
"      Diagnostic approach to and treatment of thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=related_link\">",
"      Disorders that cause hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/53/856?source=related_link\">",
"      Euthyroid hyperthyroxinemia and hypothyroxinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4165?source=related_link\">",
"      Exogenous hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12871?source=related_link\">",
"      Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=related_link\">",
"      Laboratory assessment of thyroid function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=related_link\">",
"      Overview of the clinical manifestations of hyperthyroidism in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=related_link\">",
"      Overview of the clinical utility of ultrasonography in thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=related_link\">",
"      Overview of thyroid disease in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24694?source=related_link\">",
"      Painless thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3432?source=related_link\">",
"      Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=related_link\">",
"      Patient information: Antithyroid drugs (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1828?source=related_link\">",
"      Pretibial myxedema in autoimmune thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/37/1626?source=related_link\">",
"      Reduced sensitivity to thyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13799?source=related_link\">",
"      Struma ovarii",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/23/1399?source=related_link\">",
"      Subacute thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=related_link\">",
"      Subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=related_link\">",
"      Thyroid function in nonthyroidal illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/20/327?source=related_link\">",
"      Thyrotropin (TSH)-secreting pituitary adenomas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_57_26521="Stress testing for the diagnosis of coronary heart disease";
var content_f25_57_26521=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Stress testing for the diagnosis of coronary heart disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/57/26521/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/57/26521/contributors\">",
"     Alan M Garber, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/57/26521/contributors\">",
"     Mark A Hlatky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/57/26521/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/57/26521/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/57/26521/contributors\">",
"     Patricia A Pellikka, MD, FACC, FAHA, FASE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/57/26521/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/57/26521/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/57/26521/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of coronary heart disease (CHD) as the cause of chest pain requires the use of a careful clinical history as well as additional investigation. Coronary angiography is considered the \"gold standard\" of diagnostic tests, but its limitations (invasive, costly, and does not yield physiologic information) make it appropriate as an initial study in only a minority of patients (",
"    <a class=\"graphic graphic_table graphicRef80133 \" href=\"UTD.htm?43/30/44524\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34042?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnostic approach to chest pain in adults\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation of patients presenting with chest pain suspected to be due to CHD often includes some form of non-invasive stress testing. Several tests that vary in both accuracy and cost are available. The optimal testing strategy, including the possible use of more than one test, differs according to the patient population [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major questions to be addressed before selecting one or more of the available diagnostic tests are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What is the patient's pretest risk of CHD?",
"     </li>",
"     <li>",
"      How accurate are the alternative tests?",
"     </li>",
"     <li>",
"      What are the costs and effects on health outcomes of each test?",
"     </li>",
"     <li>",
"      Do special considerations make one test more suitable in a specific patient?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of stress testing as part of a cost-effective approach to the diagnosis of CHD will be reviewed here; there will be an emphasis on the exercise ECG test. The overall approach to the patient who presents with chest pain and the advantages and limitations of the different stress testing modalities are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34042?source=see_link\">",
"     \"Diagnostic approach to chest pain in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/30/44520?source=see_link\">",
"     \"Selecting the optimal cardiac stress test\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of stress testing for prognosis and management is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=see_link\">",
"     \"Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRETEST PROBABILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An initial estimate of the likelihood of CHD, referred to as the pretest probability, is based upon the clinical history. The pretest probability determines the need for noninvasive diagnostic tests or even coronary arteriography (",
"    <a class=\"graphic graphic_table graphicRef53433 \" href=\"UTD.htm?6/8/6284\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Using the pretest probability'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The predictive models described below are based upon data from patients from a referral population, not a primary care setting. It is likely that these models overpredict the risk of CHD and they must therefore be used with caution in the primary care setting [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/4\">",
"     4",
"    </a>",
"    ]. Nevertheless, the estimates of pretest probability of CHD they provide can be used to help decide the optimal initial diagnostic test in the patient with chest pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Estimating pretest probability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large angiographic studies demonstrate that age, gender, cardiac risk factors, and a precise characterization of chest pain symptoms can be used to estimate the pretest probability of CHD. The Coronary Artery Surgery Study (CASS), for example, assessed 1465 men and 580 women with complaints of chest pain who underwent treadmill exercise testing and cardiac catheterization [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/5\">",
"     5",
"    </a>",
"    ]. Chest pain symptoms were categorized into three groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Definite or classic angina &ndash; Substernal chest discomfort characterized by all of the following characteristics: a typical quality and duration, provocation by exertion or emotional stress, and relief by rest or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"     </li>",
"     <li>",
"      Probable or atypical angina &ndash; Chest pain with two of the three above characteristics",
"     </li>",
"     <li>",
"      Nonanginal or nonischemic chest pain &ndash; Chest pain with one or none of the above characteristics",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients were excluded from the analysis if they had unstable angina or a history of prior myocardial infarction, were taking digitalis, or had left ventricular hypertrophy or left bundle branch block on their baseline ECG. Patients who had a negative exercise test (no ST segment changes) but failed to achieve at least 85 percent of their maximal predicted heart rate were also excluded as having had an inadequate test. The last group, which is representative of patients who would probably undergo further testing, had a prevalence of CHD of 67 percent in men and 28 percent in women.",
"   </p>",
"   <p>",
"    The pretest probability of CHD varied between 5 and 89 percent based upon gender and chest pain characteristics (",
"    <a class=\"graphic graphic_figure graphicRef50121 \" href=\"UTD.htm?38/21/39260\">",
"     figure 1",
"    </a>",
"    ). Within each of these subgroups, the frequency of CHD increased with age, while women with the same symptoms were less likely to have CHD than men of the same age (",
"    <a class=\"graphic graphic_table graphicRef53433 \" href=\"UTD.htm?6/8/6284\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. The higher false-positive rate on exercise ECG testing in women compared with men can be explained by the lower prevalence of CHD in women (",
"    <a class=\"graphic graphic_figure graphicRef50121 \" href=\"UTD.htm?38/21/39260\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Investigators from Duke confirmed that age, gender, and chest pain symptoms were the most powerful predictors of CHD, but showed that other characteristics also increase the probability of CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. These included diabetes mellitus, which was the strongest predictor, smoking (one-half pack per day or more within five years of the study or at least 25 pack-years), hypercholesterolemia, and Q waves or ST-T changes on the resting ECG.",
"   </p>",
"   <p>",
"    The pretest probability of finding significant obstructive coronary artery disease at the time of diagnostic coronary angiography was evaluated in a review of nearly 400,000 patients in the American College of Cardiology National Cardiovascular Data Registry [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/10\">",
"     10",
"    </a>",
"    ]. Elective noninvasive testing (some form of stress testing in most cases) was performed in 84 percent. At catheterization, only 38 percent had obstructive coronary artery disease.",
"   </p>",
"   <p>",
"    It should be kept in mind that the interpretation of the test result should be strongly influenced by the prevalence of the disease. The probability of disease in a patient with a positive test result (positive predictive value), and probability of no disease in a patient with a negative test result (negative predictive value), depends directly on the pretest probability of disease. Major differences between studies in the apparent accuracy of noninvasive testing are explained, at least in part, by this point.",
"   </p>",
"   <p>",
"    Exercise ECG testing is most useful in patients with an",
"    <strong>",
"     intermediate",
"    </strong>",
"    pretest probability (variably defined as between 25 and 75 percent or between 10 and 90 percent) (",
"    <a class=\"graphic graphic_table graphicRef53433 \" href=\"UTD.htm?6/8/6284\">",
"     table 2",
"    </a>",
"    ). Positive tests in these patients are more likely to be true positives due to the predictive accuracy of the test (",
"    <a class=\"graphic graphic_table graphicRef64463 \" href=\"UTD.htm?16/46/17132\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/6\">",
"     6",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    The test is less useful in patients with a high or low pretest probability (",
"    <a class=\"graphic graphic_table graphicRef74054 \" href=\"UTD.htm?23/59/24508\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64463 \" href=\"UTD.htm?16/46/17132\">",
"     table 3",
"    </a>",
"    ). Men over age 40 and women over age 60 with a history of typical angina pectoris already have very high pretest probabilities of CHD based upon symptoms alone (87 and 91 percent, respectively) (",
"    <a class=\"graphic graphic_table graphicRef64463 \" href=\"UTD.htm?16/46/17132\">",
"     table 3",
"    </a>",
"    ). Exercise testing is",
"    <strong>",
"     not",
"    </strong>",
"    needed for diagnosis in these patients. On the other hand, a relatively high false positive rate may be expected in patients with pretest probabilities of CHD below 25 percent (eg, men under age 40 or women under age 50 with atypical chest pain) (",
"    <a class=\"graphic graphic_table graphicRef53433 \" href=\"UTD.htm?6/8/6284\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Using the pretest probability",
"    </span>",
"    &nbsp;&mdash;&nbsp;It should be noted that asymptomatic patients have a low pretest probability of significant CHD, and generally are not screened by use of stress testing. In asymptomatic patients the risk of developing symptomatic CHD over the next ten years can be estimated using the Framingham risk score. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Asymptomatic patients with moderate or high risk of CHD may be considered for stress testing in specific situations, such as those who have high-risk occupations (eg, airline pilots). (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Summary'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NON-INVASIVE TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of tests are available to establish the diagnosis of coronary heart disease. Coronary angiography is the definitive diagnostic test for the presence of obstructive coronary artery disease. However, it is seldom used as the initial test because of its invasive nature and because the presence of a lesion does not prove that the patient's symptoms are due to ischemia.",
"   </p>",
"   <p>",
"    The following tests are available for the non-invasive diagnosis of coronary heart disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Echocardiography using either exercise or pharmacologic (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      ) stress. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=see_link\">",
"       \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radionuclide myocardial perfusion imaging using either exercise or pharmacologic stress. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=see_link\">",
"       \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=see_link\">",
"       \"Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Positron emission tomography (PET), which is not widely available. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=see_link&amp;anchor=H14#H14\">",
"       \"Assessment of myocardial viability by nuclear imaging in coronary heart disease\", section on 'Positron emission tomography'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Direct relationships have been established between coronary artery calcium (CAC) as measured by electron beam and multidetector row computed tomography and histologic, ultrasonographic, and angiographic measures of coronary disease. These observations provide a rationale for the use of CAC scanning to screen for CHD risk in asymptomatic adults suspected of having or being at risk for coronary disease. However, the presence of CAC does not prove that the lesions are sufficient to produce ischemia, and in a patient with symptoms suggestive of CAD, absence of CAC does not rule out the presence of significant CAD. Consequently, CAC testing is not recommended for evaluation of symptomatic patients, even though it is useful in asymptomatic adults to assess cardiovascular risk. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link\">",
"       \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiac computed tomography angiography (CCTA) is an emerging technique for examining coronary anatomy non-invasively. CCTA is very sensitive for the detection of coronary atherosclerosis, but not very specific, especially for the distinction between whether lesions are flow-limiting (\"significant\") or not (\"insignificant\"). Consequently, a normal CCTA is very effective at ruling out obstructive coronary disease in patients at low to intermediate pretest probability. An abnormal CCTA will often need to be followed up by further tests, such as a stress test to assess the functional significance of the lesions seen, or by invasive coronary angiography. The appropriate role of CCTA in the evaluation of patients with chest pain is currently an active area of investigation, and remains controversial. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20906?source=see_link\">",
"       \"Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These tests can be classified according to the manifestation of CHD they aim to detect: anatomic coronary artery disease, reversible myocardial ischemia, or prior myocardial infarction. Tests for myocardial ischemia can be further classified according to the method used to detect ischemia (ECG changes, perfusion defects, or wall motion abnormalities) and the method used to induce ischemia (exercise or pharmacologic stress).",
"   </p>",
"   <p>",
"    The degree of ischemia can be graded semiquantitatively by each of these methods. Ischemia can also be localized by imaging but is not localized accurately by the exercise ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/11\">",
"     11",
"    </a>",
"    ]. Ischemia in multiple coronary vascular beds indicates a worse prognosis and the likely need for more aggressive management, including coronary angiography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/30/44520?source=see_link\">",
"     \"Selecting the optimal cardiac stress test\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The different noninvasive tests vary in their diagnostic discrimination (sensitivity, specificity, and frequency of nondiagnostic results). They also vary with respect to prognostic accuracy, relative cost, and interobserver variability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Test accuracy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients in whom all of the tests can be performed, accuracy and cost are the primary factors in choosing a test. The accuracy of noninvasive tests for CHD is determined by their sensitivity and specificity (",
"    <a class=\"graphic graphic_figure graphicRef50121 \" href=\"UTD.htm?38/21/39260\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensitivity reflects a test's ability to \"rule out\" a given disease if the test is negative",
"     </li>",
"     <li>",
"      Specificity reflects a test's ability to \"rule in\" a given disease if the test is positive",
"     </li>",
"     <li>",
"      Predictive accuracy is the percentage of test responses (both positive and negative) that are true; this measure depends upon both test characteristics and disease prevalence in the tested population",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sensitivity of the noninvasive tests for diagnosing CHD depends upon the population studied, the definition of coronary disease used (&ge;70 and &ge;50 percent diameter stenosis are common definitions), and the extent of coronary disease. There are also procedure-specific factors. With exercise ECG testing, for example, test performance can be affected by exercise end points, the number of ECG leads monitored, and most importantly by the ECG criteria used for a positive test (",
"    <a class=\"graphic graphic_table graphicRef80746 \" href=\"UTD.htm?16/33/16923\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=see_link\">",
"     \"Performance of exercise ECG testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sensitivity and specificity of a given test depend upon the definition of a positive result. As an example, if ST segment depression with exercise is used as the test end point, 1 mm of ST segment depression is more sensitive but less specific than 2 mm of ST segment depression (",
"    <a class=\"graphic graphic_table graphicRef59283 \" href=\"UTD.htm?3/23/3451\">",
"     table 6",
"    </a>",
"    ). In general, the application of more stringent criteria for a positive result decreases sensitivity and increases specificity, while the application of less stringent criteria increases sensitivity and decreases specificity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Comparison of tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;No study has compared the diagnostic accuracy of all available noninvasive tests in the same group of patients and there are few studies that compare results of even two noninvasive tests in the same patients. Consequently, the relative performance of alternative tests is based upon the synthesis of multiple studies of variable design.",
"   </p>",
"   <p>",
"    A meta-analysis compared the test performance in patients with an intermediate pretest risk of CHD (25 to 75 percent) of the following tests: exercise ECG testing, planar thallium imaging, SPECT perfusion imaging, stress echocardiography, and positron emission tomography (PET), each of which was followed by coronary angiography if the test was positive [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/12\">",
"     12",
"    </a>",
"    ]. Not surprisingly, much more data was available about exercise ECG testing. The following values for sensitivity and specificity were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise ECG testing &ndash; 68 and 77 percent in 132 studies of over 24,000 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Planar thallium rMPI &ndash; 79 and 73 percent in six studies of 510 patients",
"     </li>",
"     <li>",
"      SPECT rMPI &ndash; 88 and 77 percent in 10 studies of 1174 patients",
"     </li>",
"     <li>",
"      Stress echocardiography &ndash; 76 and 88 percent in six studies of 510 patients",
"     </li>",
"     <li>",
"      PET scanning &ndash; 91 and 82 percent in three studies of 206 patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Imaging tests are more sensitive than the exercise ECG in the detection of severe (three vessel and left main) disease. In another meta-analysis, the sensitivity for severe disease was 93 to 98 percent with planar thallium imaging, stress echocardiography, and SPECT perfusion imaging compared with 86 percent for exercise ECG testing [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/14\">",
"     14",
"    </a>",
"    ]. The sensitivity of exercise ECG testing for severe disease does not appear to be increased by using a combination of test variables; in a study using the Duke Treadmill Score, 87 percent of patients with three vessel or left main disease had an intermediate or high risk score [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H11#H11\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Duke treadmill score'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The authors concluded that test selection should reflect local variation in test accuracy. Despite the relatively poor diagnostic discrimination of exercise ECG testing compared to other forms of stress testing, it remains widely used because of lower cost and, with use of a risk score such as the Duke Treadmill Score, it effectively identifies men at low and high clinical risk (",
"    <a class=\"graphic graphic_figure graphicRef59562 \" href=\"UTD.htm?34/10/34989\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/15\">",
"     15",
"    </a>",
"    ]. However, it may be less effective for risk stratification in women (",
"    <a class=\"graphic graphic_figure graphicRef79590 \" href=\"UTD.htm?14/55/15230\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H11#H11\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Duke treadmill score'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H15#H15\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Women'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A second meta-analysis compared the performance of exercise echocardiography and exercise SPECT; it included a different but overlapping set of studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/17\">",
"     17",
"    </a>",
"    ]. Both tests had similar sensitivity (85 and 87 percent), but specificity was significantly lower with exercise SPECT (64 versus 77 percent). Both tests had better performance than exercise ECG testing (sensitivity 52 percent and specificity 71 percent).",
"   </p>",
"   <p>",
"    Although there were slight differences between radionuclides (sestamibi and thallium), they did not appear to have substantial effects upon the accuracy of radionuclide myocardial perfusion imaging. The method of inducing ischemia did not appear to have a large effect on the diagnostic accuracy of imaging studies, although one meta-analysis suggested that echocardiography with exercise stress was more sensitive than echocardiography with pharmacologic stress [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosing coronary artery disease is more difficult in women than men for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women are less likely to present with (or report during treadmill testing) typical angina.",
"     </li>",
"     <li>",
"      False positives test results during exercise ECG testing are more common.",
"     </li>",
"     <li>",
"      Problems with accuracy negatively impact results of cost-effectiveness analyses in women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnostic value of the exercise ECG testing alone in women is limited by a lower specificity of ST segment changes compared with men and a lower sensitivity than stress cardiac imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Some of the important causes of this lower predictive accuracy in women are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A lower prevalence of coronary disease than in men of the same age [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inadequate exercise to induce ischemia during stress testing, especially among elderly women.",
"     </li>",
"     <li>",
"      A higher prevalence of nonobstructive CAD and microvascular disease which, while not associated with obstructive disease on angiography, can cause symptoms and are associated with future cardiac events [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A higher incidence of false-positive ST segment depression during exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/5,21\">",
"       5,21",
"      </a>",
"      ]. This limitation may in part be a consequence of inadequate warm-up using the standard Bruce exercise protocol rather than a modified Bruce protocol or other protocols better matched to the patient's exercise capacity. False positive ECG changes can be seen if the first stages of exercise are too strenuous, and a standard Bruce protocol starts too fast for many patients. In patients with limited exercise capacity, the test should be modified with a more gradual start. This is not always done, and this tends to be more of a problem for women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In CASS, the higher false-positive rate on exercise ECG testing in women compared to men could be explained by the lower prevalence of CHD in women [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal diagnostic strategy, from a standpoint of both accuracy and cost effectiveness, is not yet known in women with suspected CHD. The WOMEN trial randomized 824 women with an intermediate pre-test probability of CHD to either an exercise ECG or exercise myocardial perfusion imaging. The study found that the exercise ECG strategy led to more abnormal initial tests, and thus required more follow-up testing, but had lower overall costs and equivalent clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Duke Treadmill Score",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the Duke Treadmill Score is typically used for prognosis, it may also be used to evaluate the predictive value of stress testing. The Duke Treadmill Score is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H11#H11\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Duke treadmill score'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Combination of test data",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not uncommon for patients to have both an exercise ECG and a stress imaging study, either as components of a single test or as separate tests. It is important to pay attention to the results of both the exercise ECG findings and the imaging results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with severe abnormalities on both tests are highly likely to have CHD and are at high risk for events. Such patients should be considered strongly for invasive evaluation if revascularization would be considered to either improve prognosis or the quality of life.",
"     </li>",
"     <li>",
"      When both tests are normal at a high level of stress, the results are doubly reassuring and the patient is not likely to benefit from invasive evaluation.",
"     </li>",
"     <li>",
"      The presence of a markedly abnormal perfusion scan (large perfusion defect or multiple areas of reversibility) is indicative of high risk, irrespective of the results of treadmill testing [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/13,23\">",
"       13,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with a high level of exercise who have a normal exercise ECG test but a small perfusion defect in one vascular territory have a low risk of cardiac events. Such patients should be managed conservatively, with referral for angiography if symptoms cannot be controlled with medical therapy.",
"     </li>",
"     <li>",
"      Patients with suspected CHD who are at intermediate risk based upon the exercise ECG test (Duke Treadmill Score -10 to 4) but have a normal or near-normal exercise perfusion image are also at low risk for a cardiac event. In a study of 4649 such patients, the seven year rates of cardiovascular survival and cardiac survival free of myocardial infarction were 99 and 97 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/24\">",
"       24",
"      </a>",
"      ]. Seven year event cardiac survival was lower (89 percent) in patients with cardiac enlargement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H11#H11\">",
"       \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Duke treadmill score'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who have a strongly positive exercise ECG test (eg, Duke Treadmill Score &lt;-11) are generally at high risk for mortality (",
"      <a class=\"graphic graphic_figure graphicRef59562 \" href=\"UTD.htm?34/10/34989\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     EXERCISE ECG TEST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise ECG testing is the most commonly used noninvasive test because it is simple and inexpensive. The performance of this test is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=see_link\">",
"     \"Performance of exercise ECG testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Advantages of exercise stress",
"    </span>",
"   </p>",
"   <p>",
"    As a general rule, exercise stress provides more information than pharmacologic stress for the following reasons (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/30/44520?source=see_link&amp;anchor=H458218813#H458218813\">",
"     \"Selecting the optimal cardiac stress test\", section on 'Exercise'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise documents the workload that induces ischemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=see_link&amp;anchor=H12#H12\">",
"       \"Performance of exercise ECG testing\", section on 'Treadmill testing protocols'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exercise capacity and hemodynamic responses are predictors of prognosis independent of ischemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H2#H2\">",
"       \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Adverse predictors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ischemia at a low workload indicates a greater likelihood of severe disease and a worse prognosis than does the same degree of ischemia at a high workload. Furthermore, the inability to exercise is itself associated with increased cardiovascular risk. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=see_link&amp;anchor=H5#H5\">",
"       \"Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease\", section on 'Advantages of exercise stress'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=see_link&amp;anchor=H7#H7\">",
"       \"Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease\", section on 'Duke treadmill score'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Limitations of exercise stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exercise ECG cannot be interpreted in the presence of resting ST segment changes, left ventricular hypertrophy, left bundle branch block, a ventricular paced rhythm, or the Wolff Parkinson White syndrome. The patient must also be able to exercise adequately, since failure to achieve at least 85 percent of the predicted maximal heart rate is considered inadequate to rule out ischemic heart disease if the test is otherwise negative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=see_link\">",
"     \"Performance of exercise ECG testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For such patients who cannot exercise, have baseline ECG abnormalities that could interfere with exercise ECG testing, or in whom a previously performed exercise ECG test suggests intermediate risk, a number of alternative noninvasive tests are available (",
"    <a class=\"graphic graphic_algorithm graphicRef87155 \" href=\"UTD.htm?26/46/27363\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    Choice of stress test modality in patients with LBBB or a paced ventricular rhythm is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=see_link\">",
"     \"Stress testing in patients with left bundle branch block or a paced ventricular rhythm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Posttest probability",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the exercise ECG test is performed, the sensitivity and specificity can be combined with the pretest risk to determine the posttest probability of CHD",
"   </p>",
"   <p>",
"    The pretest probability, in conjunction with the sensitivity and specificity of the test, can also be used to determine the posttest probability of CHD (",
"    <a class=\"graphic graphic_figure graphicRef81630 graphicRef50189 \" href=\"UTD.htm?34/18/35119\">",
"     figure 4A-B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pretest probability'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Among patients with a very high pretest probability, a positive test is highly predictive of CHD, but a negative test does not exclude CHD. Conversely, among patients with a very low pretest probability, a positive test is likely to be a false-positive result, while a negative test is highly predictive of the absence of CHD (",
"    <a class=\"graphic graphic_table graphicRef64463 \" href=\"UTD.htm?16/46/17132\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These concepts were illustrated in an example published in society guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with a low pretest probability of CHD (5 percent), the positive predictive value (or posttest probability) of a positive test is only 21 percent (assuming a test sensitivity of 50 percent and a specificity of 90 percent). Thus, if 1000 such patients are tested, 120 will have a positive result, of whom 95 will not have significant CHD. The high likelihood of a false-positive result must be considered before ordering a noninvasive test in this group of patients.",
"     </li>",
"     <li>",
"      In patients with a high pretest probability of CHD (90 percent), a positive test increases the probability of disease to 98 percent, while a negative result lowers the probability to only 83 percent. Thus, a noninvasive test may have little diagnostic information to offer in this group of patients. However, it may be useful for prognostic purposes. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Our approach'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=see_link\">",
"       \"Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with an intermediate pretest probability of CHD (50 percent), a positive test increases the likelihood of disease to 83 percent while a negative test decreases the likelihood to 36 percent. It is this group that is most likely to benefit from a noninvasive diagnostic test.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     How to use the results",
"    </span>",
"    &nbsp;&mdash;&nbsp;No further evaluation is necessary if the maximum stress test is negative and the patient can achieve an adequate work level, although risk factor modification with or without anti-ischemic therapy is warranted in any individual.",
"   </p>",
"   <p>",
"    Further testing and treatment for suspected or likely coronary artery disease is determined in part by the degree of abnormality found of the stress test. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=see_link&amp;anchor=H16#H16\">",
"     \"Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease\", section on 'Choice of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a test result suggestive of high risk are referred for angiography unless they have severe comorbidities that are likely to limit life expectancy or prevent revascularization.",
"     </li>",
"     <li>",
"      Patients with a low risk test are generally managed medically.",
"     </li>",
"     <li>",
"      Patients with an intermediate risk test are usually referred for a stress imaging study or, if left ventricular function is known to be impaired, angiography.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All patients with documented CHD should be treated with aggressive risk factor reduction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR DIAGNOSTIC NON-INVASIVE TESTING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     2012 ACC/AHA guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2012 American College of Physicians",
"    <span class=\"nowrap\">",
"     (ACP)/American",
"    </span>",
"    College of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC)/American",
"    </span>",
"    Heart Association (AHA) guidelines for stable angina recommend that exercise is the preferred form of stress for patients who have at least moderate physical functioning and thus are likely to achieve an adequate workload (defined as &ge;85 percent of their age-predicted maximum heart rate, which is equal to 0.85 times [220 - age]) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/1\">",
"     1",
"    </a>",
"    ]. Exercise stress provides more information than pharmacologic stress concerning patient symptoms, cardiovascular function, and the hemodynamic response during usual forms of activity.",
"   </p>",
"   <p>",
"    The inability to perform an exercise test is in itself a negative prognostic factor in patients with CHD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=see_link&amp;anchor=H5#H5\">",
"     \"Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease\", section on 'Advantages of exercise stress'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2012",
"    <span class=\"nowrap\">",
"     ACP/ACC/AHA",
"    </span>",
"    guidelines on diagnosis of chronic stable angina considered the exercise ECG without imaging to be preferred as the initial test in patients with an intermediate pretest probability of CHD (between 10 and 90 percent) based upon age, gender, and symptoms (",
"    <a class=\"graphic graphic_table graphicRef53433 \" href=\"UTD.htm?6/8/6284\">",
"     table 2",
"    </a>",
"    ), including patients with complete right bundle branch block or &lt;1 mm of ST depression at rest [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The guidelines suggest that candidates for stress testing with imaging rather than exercise ECG include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with abnormalities that can interfere with interpretation of the ECG, such as left ventricular hypertrophy, left bundle branch block, or a ventricular-paced rhythm; patients with &gt;0.5 mm of ST-segment depression at rest; and patients taking digitalis. Stress testing in patients with LBBB or a paced ventricular rhythm is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=see_link\">",
"       \"Stress testing in patients with left bundle branch block or a paced ventricular rhythm\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who cannot exercise to a sufficient degree to obtain an adequate routine exercise test should undergo pharmacologic stress imaging.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines acknowledged that the exercise stress testing for diagnosing CHD is less accurate in women than in men [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26521/abstract/25\">",
"     25",
"    </a>",
"    ], and that diagnostic accuracy may be improved by use of stress imaging. For women with a normal resting ECG and at least moderate clinician functioning (to allow for adequate exercise stress), an exercise ECG is the preferred initial non-invasive test.",
"   </p>",
"   <p>",
"    The guidelines also suggest that beta blockers and other anti-ischemic drugs be withheld for four to five half-lives (typically around 48 hours) prior to noninvasive testing when possible; the drugs should be withdrawn gradually.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our approach varies with the pretest probability of disease. We strongly recommend that a specific clinical assessment of pretest probability be made prior to testing, based upon objective data (",
"    <a class=\"graphic graphic_table graphicRef53433 \" href=\"UTD.htm?6/8/6284\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the patient with a high pretest probability of CHD (",
"    <a class=\"graphic graphic_table graphicRef53433 \" href=\"UTD.htm?6/8/6284\">",
"     table 2",
"    </a>",
"    ), noninvasive testing is not necessary for diagnosis, because a negative result is likely to be a false negative (",
"    <a class=\"graphic graphic_table graphicRef64463 \" href=\"UTD.htm?16/46/17132\">",
"     table 3",
"    </a>",
"    ). However, noninvasive testing may be important in determining prognosis and management. Coronary angiography documents the extent of disease but does not always provide sufficient information upon which to base therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=see_link\">",
"     \"Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend that a stress test be performed in patients with a high pretest probability of CHD. In most cases, the stress test should be performed prior to coronary angiography to identify those who may benefit from revascularization. However, in patients with especially worrisome symptoms, such as angina with very limited exertion, obtaining angiography first to identify severe left main or three vessel coronary disease may be prudent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=see_link\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the resting ECG is normal, we recommend standard exercise ECG testing, since the exercise response will be an important factor in determining prognosis. If the resting ECG has abnormalities that will interfere with interpretation during exercise or if localization of ischemia is expected to be important, we recommend an exercise test with imaging (eg, echocardiography or perfusion imaging with sestamibi). For patients who cannot exercise, pharmacologic stress testing should be performed.",
"   </p>",
"   <p>",
"    In the patient with an intermediate pretest probability of CHD (",
"    <a class=\"graphic graphic_table graphicRef53433 \" href=\"UTD.htm?6/8/6284\">",
"     table 2",
"    </a>",
"    ), the main objective is to clarify the diagnosis. We agree with the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines which recommend exercise ECG testing in this setting. Some experts prefer an exercise test with imaging because the higher sensitivity and specificity provides more diagnostic discrimination than a simple exercise ECG. If the patient is unlikely to achieve an adequate level of exercise, a pharmacologic stress test with imaging should be performed.",
"   </p>",
"   <p>",
"    In the patient with a low pretest probability of disease (",
"    <a class=\"graphic graphic_table graphicRef53433 \" href=\"UTD.htm?6/8/6284\">",
"     table 2",
"    </a>",
"    ), no further testing is recommended by the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines. However, the prognostic information provided by exercise ECG testing can be of value in selected patients in this setting. As an example, if a patient with atypical chest pain is found on exercise ECG testing to have excellent exercise capacity without significant ECG changes, the need for any further testing in the future can be avoided unless symptoms change significantly.",
"   </p>",
"   <p>",
"    A modified exercise protocol is generally necessary for sedentary or elderly patients to permit them to warm up gradually and to exercise between six and 12 minutes. When the initial workload is too demanding, the likelihood of false positive ECG findings increases.",
"   </p>",
"   <p>",
"    The imaging options (echocardiography and rMPI) have different advantages and disadvantages in different patient groups. All of the tests contribute important prognostic information. Stress echocardiography provides information about left ventricular function, ejection fraction, and valvular heart disease, while stress perfusion imaging is the most useful test for determining the size and location of an area of ischemia. Local expertise and availability may affect the choice of imaging modality for stress testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/30/44520?source=see_link\">",
"     \"Selecting the optimal cardiac stress test\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=see_link\">",
"       \"Patient information: ECG and stress test (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/30/32226?source=see_link\">",
"       \"Patient information: Nuclear heart testing (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of patients presenting with chest pain suspected to be due to CHD often includes some form of non-invasive stress testing. Several tests that vary in both accuracy and cost are available. The optimal testing strategy, including the possible use of more than one test, differs according to the patient population and in part upon the specific limitations of each test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=see_link\">",
"     \"Performance of exercise ECG testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=see_link\">",
"     \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=see_link\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=see_link\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following are important points discussed in this topic:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial estimate of the likelihood of CHD, referred to as the pretest probability is based upon the clinical history and it determines the need for noninvasive diagnostic tests or even coronary arteriography (",
"      <a class=\"graphic graphic_table graphicRef53433 \" href=\"UTD.htm?6/8/6284\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Estimating pretest probability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of tests are available for the non-invasive diagnosis of coronary heart disease. The different noninvasive tests vary in their diagnostic discrimination (sensitivity, specificity, and frequency of nondiagnostic results) and they also vary with respect to prognostic accuracy, relative cost, and interobserver variability. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Non-invasive tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exercise ECG testing is the most commonly used noninvasive test because it is simple and inexpensive. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Exercise ECG test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our approach to testing varies with the pretest probability of disease. We strongly recommend that a specific clinical assessment of pretest probability be made prior to testing, based upon objective data (",
"      <a class=\"graphic graphic_table graphicRef53433 \" href=\"UTD.htm?6/8/6284\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Our approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The further management of patients with negative, low, intermediate, or high-risk tests is discussed above. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'How to use the results'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26521/abstract/1\">",
"      Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:e354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26521/abstract/2\">",
"      Qaseem A, Fihn SD, Williams S, et al. Diagnosis of stable ischemic heart disease: summary of a clinical practice guideline from the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. Ann Intern Med 2012; 157:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26521/abstract/3\">",
"      Lee TH, Boucher CA. Clinical practice. Noninvasive tests in patients with stable coronary artery disease. N Engl J Med 2001; 344:1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26521/abstract/4\">",
"      Sox HC Jr, Hickam DH, Marton KI, et al. Using the patient's history to estimate the probability of coronary artery disease: a comparison of primary care and referral practices. Am J Med 1990; 89:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26521/abstract/5\">",
"      Weiner DA, Ryan TJ, McCabe CH, et al. Exercise stress testing. Correlations among history of angina, ST-segment response and prevalence of coronary-artery disease in the Coronary Artery Surgery Study (CASS). N Engl J Med 1979; 301:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26521/abstract/6\">",
"      Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. N Engl J Med 1979; 300:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26521/abstract/7\">",
"      Chaitman BR, Bourassa MG, Davis K, et al. Angiographic prevalence of high-risk coronary artery disease in patient subsets (CASS). Circulation 1981; 64:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26521/abstract/8\">",
"      Pryor DB, Harrell FE Jr, Lee KL, et al. Estimating the likelihood of significant coronary artery disease. Am J Med 1983; 75:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26521/abstract/9\">",
"      Pryor DB, Shaw L, McCants CB, et al. Value of the history and physical in identifying patients at increased risk for coronary artery disease. Ann Intern Med 1993; 118:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26521/abstract/10\">",
"      Patel MR, Peterson ED, Dai D, et al. Low diagnostic yield of elective coronary angiography. N Engl J Med 2010; 362:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26521/abstract/11\">",
"      Mark DB, Hlatky MA, Harrell FE Jr, et al. Exercise treadmill score for predicting prognosis in coronary artery disease. Ann Intern Med 1987; 106:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26521/abstract/12\">",
"      Garber AM, Solomon NA. Cost-effectiveness of alternative test strategies for the diagnosis of coronary artery disease. Ann Intern Med 1999; 130:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26521/abstract/13\">",
"      Gianrossi R, Detrano R, Mulvihill D, et al. Exercise-induced ST depression in the diagnosis of coronary artery disease. A meta-analysis. Circulation 1989; 80:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26521/abstract/14\">",
"      Detrano R, Gianrossi R, Froelicher V. The diagnostic accuracy of the exercise electrocardiogram: a meta-analysis of 22 years of research. Prog Cardiovasc Dis 1989; 32:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26521/abstract/15\">",
"      Shaw LJ, Peterson ED, Shaw LK, et al. Use of a prognostic treadmill score in identifying diagnostic coronary disease subgroups. Circulation 1998; 98:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26521/abstract/16\">",
"      Alexander KP, Shaw LJ, Shaw LK, et al. Value of exercise treadmill testing in women. J Am Coll Cardiol 1998; 32:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26521/abstract/17\">",
"      Fleischmann KE, Hunink MG, Kuntz KM, Douglas PS. Exercise echocardiography or exercise SPECT imaging? A meta-analysis of diagnostic test performance. JAMA 1998; 280:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26521/abstract/18\">",
"      Morise AP, Diamond GA. Comparison of the sensitivity and specificity of exercise electrocardiography in biased and unbiased populations of men and women. Am Heart J 1995; 130:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26521/abstract/19\">",
"      Melin JA, Wijns W, Vanbutsele RJ, et al. Alternative diagnostic strategies for coronary artery disease in women: demonstration of the usefulness and efficiency of probability analysis. Circulation 1985; 71:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26521/abstract/20\">",
"      Williams MJ, Marwick TH, O'Gorman D, Foale RA. Comparison of exercise echocardiography with an exercise score to diagnose coronary artery disease in women. Am J Cardiol 1994; 74:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26521/abstract/21\">",
"      Sketch MH, Mohiuddin SM, Lynch JD, et al. Significant sex differences in the correlation of electrocardiographic exercise testing and coronary arteriograms. Am J Cardiol 1975; 36:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26521/abstract/22\">",
"      Shaw LJ, Mieres JH, Hendel RH, et al. Comparative effectiveness of exercise electrocardiography with or without myocardial perfusion single photon emission computed tomography in women with suspected coronary artery disease: results from the What Is the Optimal Method for Ischemia Evaluation in Women (WOMEN) trial. Circulation 2011; 124:1239.",
"     </a>",
"    </li>",
"    <li>",
"     Beller G. Detection of coronary artery disease. In: Clinical Nuclear Cardiology, Saunders, Philadelphia 1995. p.82.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26521/abstract/24\">",
"      Gibbons RJ, Hodge DO, Berman DS, et al. Long-term outcome of patients with intermediate-risk exercise electrocardiograms who do not have myocardial perfusion defects on radionuclide imaging. Circulation 1999; 100:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26521/abstract/25\">",
"      Mieres JH, Shaw LJ, Arai A, et al. Role of noninvasive testing in the clinical evaluation of women with suspected coronary artery disease: Consensus statement from the Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association. Circulation 2005; 111:682.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1534 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-6DAE62D42F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_57_26521=[""].join("\n");
var outline_f25_57_26521=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRETEST PROBABILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Estimating pretest probability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Using the pretest probability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NON-INVASIVE TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Test accuracy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Comparison of tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Duke Treadmill Score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Combination of test data",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      EXERCISE ECG TEST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Advantages of exercise stress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Limitations of exercise stress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Posttest probability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      How to use the results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      INDICATIONS FOR DIAGNOSTIC NON-INVASIVE TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      2012 ACC/AHA guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1534\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1534|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?26/46/27363\" title=\"algorithm 1\">",
"      Algorithm for choosing the optimal cardiac stress test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1534|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/21/39260\" title=\"figure 1\">",
"      Definitions of test accuracy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/10/34989\" title=\"figure 2\">",
"      Duke Treadmill Score and survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/55/15230\" title=\"figure 3\">",
"      Duke Treadmill Score and prognosis by gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/0/1037\" title=\"figure 4A\">",
"      Positive predict value ETT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/19/2367\" title=\"figure 4B\">",
"      Value ETT Bayes theorem",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1534|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/30/44524\" title=\"table 1\">",
"      ACC AHA angiography dx CAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/8/6284\" title=\"table 2\">",
"      Pretest probability of CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/46/17132\" title=\"table 3\">",
"      Pretest probability of CHD in CASS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/59/24508\" title=\"table 4\">",
"      ACC AHA ETT diagnosis CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/33/16923\" title=\"table 5\">",
"      Factors accuracy exercise test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/23/3451\" title=\"table 6\">",
"      ECG exercise and ST depression",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=related_link\">",
"      Assessment of myocardial viability by nuclear imaging in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=related_link\">",
"      Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34042?source=related_link\">",
"      Diagnostic approach to chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=related_link\">",
"      Exercise ECG testing to determine prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=related_link\">",
"      Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=related_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20906?source=related_link\">",
"      Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/30/32226?source=related_link\">",
"      Patient information: Nuclear heart testing (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=related_link\">",
"      Performance of exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/30/44520?source=related_link\">",
"      Selecting the optimal cardiac stress test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=related_link\">",
"      Stress echocardiography in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=related_link\">",
"      Stress testing in patients with left bundle branch block or a paced ventricular rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=related_link\">",
"      Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=related_link\">",
"      Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_57_26522="Traumatic gastrointestinal injury in the adult patient";
var content_f25_57_26522=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Traumatic gastrointestinal injury in the adult patient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/57/26522/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/57/26522/contributors\">",
"     Elizabeth Benjamin, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/57/26522/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/57/26522/contributors\">",
"     Heidi L Frankel, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/57/26522/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/57/26522/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/57/26522/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1065773\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal injury of the stomach, small bowel, colon, or rectum can be due to blunt or penetrating trauma. The nature and severity of the injury depends upon the injury mechanism. Injuries range from minor bruising to complete devascularization for blunt injuries and small perforations to devascularization for penetrating injuries. Associated solid organ injury is common.",
"   </p>",
"   <p>",
"    The duodenum is frequently injured in association with the pancreas and the management of these combined injuries is complex. The diagnosis and management of duodenal injuries are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22266?source=see_link\">",
"     \"Management of duodenal and pancreatic trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis and management of gastrointestinal injury (except duodenum) due to trauma is reviewed here. The general approach to the abdominal trauma patient is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link\">",
"     \"Initial evaluation and management of blunt abdominal trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12776?source=see_link\">",
"     \"Initial evaluation and management of abdominal stab wounds in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3943?source=see_link\">",
"     \"Initial evaluation and management of abdominal gunshot wounds in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H197204457\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H169106595\">",
"    <span class=\"h2\">",
"     Stomach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stomach is located in the left upper quadrant of the abdomen but can occupy other areas of the abdomen depending upon its degree of distention, phase of diaphragmatic excursion, and the positioning of the individual at the time of the injury. Anteriorly, the stomach is adjacent to the left lobe of the liver, diaphragm, colon, and anterior abdominal wall. Posteriorly, the stomach is adjacent to the pancreas, spleen, left kidney and adrenal gland, splenic artery, left diaphragm, transverse mesocolon, and colon (",
"    <a class=\"graphic graphic_figure graphicRef56689 \" href=\"UTD.htm?40/59/41907\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The blood supply of the stomach is from the gastric arteries. The left gastric artery, which is derived from the celiac artery, courses along the lesser curvature of the stomach and anastomoses with the right gastric artery, which is a branch of the common hepatic artery (",
"    <a class=\"graphic graphic_figure graphicRef56689 \" href=\"UTD.htm?40/59/41907\">",
"     figure 1",
"    </a>",
"    ). The right and left gastroepiploic arteries arise from the gastroduodenal artery and splenic arteries, respectively, and anastomose along the greater curvature. The short gastric arteries arise from the splenic artery and supply the fundus of the stomach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H169106603\">",
"    <span class=\"h2\">",
"     Small bowel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The small bowel is anatomically divided into three portions: the duodenum, jejunum, and ileum. The anatomy of the duodenum is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22266?source=see_link&amp;anchor=H651340813#H651340813\">",
"     \"Management of duodenal and pancreatic trauma in adults\", section on 'Duodenal and pancreatic anatomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The jejunum begins at the ligament of Treitz, and there are no true anatomic boundaries that delineate the jejunum from ileum. The jejunum tends to have more adipose tissue in the associated mesentery, and its vascular arcades are fewer and longer when compared with the ileum (",
"    <a class=\"graphic graphic_figure graphicRef85571 \" href=\"UTD.htm?37/19/38197\">",
"     figure 2",
"    </a>",
"    ). The jejunum and ileum measure between 6 and 7 meters long and are attached to the posterior abdominal wall by the mesentery.",
"   </p>",
"   <p>",
"    The arterial supply, venous drainage, autonomic nerves, lymph nodes, and a variable amount of adipose tissue are contained between the layers of the small bowel mesentery. The superior mesenteric artery (SMA) provides the blood supply to the jejunum and ileum, and originates from the aorta approximately one centimeter below the origin of the celiac trunk (",
"    <a class=\"graphic graphic_figure graphicRef51087 \" href=\"UTD.htm?42/14/43234\">",
"     figure 3",
"    </a>",
"    ). The superior mesenteric vein lies anterior and to the right of the artery and joins the splenic vein to form the portal vein behind the neck of the pancreas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H169106611\">",
"    <span class=\"h2\">",
"     Colon and rectum",
"    </span>",
"    &nbsp;&mdash;&nbsp;The colon and rectum occupy retroperitoneal and intraperitoneal spaces, in close approximation to solid organs (",
"    <a class=\"graphic graphic_figure graphicRef60998 \" href=\"UTD.htm?31/6/31846\">",
"     figure 4",
"    </a>",
"    ). The ascending and descending colon are retroperitoneal, while the transverse colon, which extends from the hepatic flexure to the splenic flexure, is intraperitoneal. The sigmoid colon continues from the descending colon, ending where the teniae converge to form the rectum. The rectum is the distal continuation of the colon, measuring 12 to 15 cm in length. The rectum lies anterior to the three inferior sacral vertebrae, the coccyx, and sacral vessels, and is posterior to the bladder in men and the vagina in women. The anterior upper two-thirds of the rectum are located intraperitoneally and the remainder is extraperitoneal.",
"   </p>",
"   <p>",
"    The blood supply to the colon is derived from the superior (SMA) and inferior mesenteric arteries (IMA), and internal iliac artery (",
"    <a class=\"graphic graphic_figure graphicRef73756 \" href=\"UTD.htm?40/32/41479\">",
"     figure 5",
"    </a>",
"    ). The SMA, ileocolic, right colic, and middle colic arteries supply the cecum, right colon, and first portion of the transverse colon respectively. The venous outflow generally follows the arterial supply (",
"    <a class=\"graphic graphic_figure graphicRef81960 \" href=\"UTD.htm?3/3/3127\">",
"     figure 6",
"    </a>",
"    ). The transverse colon derives its blood supply from both the SMA and IMA. The watershed area between these vessels is at risk for ischemia. The descending and sigmoid colon are supplied by the left colic artery and the superior sigmoid artery, branches of the IMA. The rectum is supplied by the superior, middle rectal, and inferior rectal artery, which originate from the internal iliac artery. Venous drainage from the rectum is from the superior rectal and middle rectal veins draining to the inferior mesenteric veins, and the inferior rectal veins draining to the internal pudendal veins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H533808630\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal injury can be due to blunt mechanisms (motor vehicle crash, pedestrian injury, falls) or penetrating mechanisms (knife, gunshot, shotgun). Most blunt gastrointestinal injuries are due to motor vehicle crashes with an increased risk for those wearing a seatbelt",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in the front seat passenger position. A multi-institutional prospective review of 95 trauma centers by The Eastern Association for the Surgery of Trauma (EAST Hollow Viscus Injury in Blunt Trauma Study) identified 275,557 trauma admissions and found that patients involved in a motor vehicle crash are 1.5 times more likely to sustain a gastrointestinal injury compared with other mechanisms of blunt abdominal trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22697869\">",
"    <span class=\"h2\">",
"     Blunt injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of blunt gastrointestinal injury is typically due to crushing of the bowel between the solid structures of the body such as the spine or pelvis and steering wheel, seatbelt, or handle bar (bicycle, motorcycle) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/3\">",
"     3",
"    </a>",
"    ]. In the EAST Hollow Viscus Injury Study, the incidence of gastrointestinal injury among patients receiving an abdominal workup for trauma was 3.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/2\">",
"     2",
"    </a>",
"    ]. In order of frequency, gastrointestinal injury occurred more commonly in the small bowel",
"    <span class=\"nowrap\">",
"     (jejunum/ileum)",
"    </span>",
"    followed by",
"    <span class=\"nowrap\">",
"     colon/rectum,",
"    </span>",
"    duodenum, stomach, and appendix. The risk for full-thickness injury followed the same pattern. The mechanism of injury to specific organs following blunt trauma is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stomach",
"      <strong>",
"       &ndash;",
"      </strong>",
"      Rupture of the stomach is relatively uncommon because of its relatively protected anatomic location. The incidence of stomach perforation following blunt trauma ranges from 0.02 to 1.7 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/4-8\">",
"       4-8",
"      </a>",
"      ]. When rupture does occur, the anterior wall is more commonly affected and approximately 95 percent of stomach injuries are associated with injuries to other solid and hollow organs [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/5,8\">",
"       5,8",
"      </a>",
"      ]. The risk of perforation may be higher for patients with pre-existing gastric distention, such as following a meal [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/4\">",
"       4",
"      </a>",
"      ]. Increasing severity of abdominal injury is associated with a greater risk for gastric injury. Compared with patients who have small bowel",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      colon injuries, patients with blunt gastric injuries have a higher Injury Severity Score (ISS) (22 versus 17) and a higher percentage of patients with a chest Abbreviated Injury Scores (AIS)&gt;2 (36 versus 12 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Small",
"      <strong>",
"      </strong>",
"      bowel",
"      <strong>",
"      </strong>",
"      &ndash; Small bowel injury is associated with injury mechanisms that include front seat passenger position in motor vehicle crashes, falls, and pedestrians struck by automobiles [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/2\">",
"       2",
"      </a>",
"      ]. Small bowel injuries associated with blunt trauma were contusions limited to the bowel serosa in contrast to penetrating injuries that typically result in perforation. However, almost one-third of mesenteric injuries resulted in a devascularized bowel segment that ultimately required resection [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/9\">",
"       9",
"      </a>",
"      ]. If a perforation was identified, it was most likely to be in the jejunum. Blunt small intestinal injury can be difficult to detect because a full-thickness bowel injury may not be immediately present in contrast to the immediate intestinal leakage that is typical of penetrating intestinal injury. Following blunt intestinal injury, full-thickness necrosis and intestinal rupture may develop over days.",
"     </li>",
"     <li>",
"      Colon",
"      <strong>",
"      </strong>",
"      and",
"      <strong>",
"      </strong>",
"      rectum &ndash; Colonic and rectal injuries are relatively uncommon. Blunt injury to the mesentery occurs commonly at transition points where the mobile portions of the colon become fixed retroperitoneally, such as in the region of the ileocecal valve and sigmoid colon. The rectum can be injured in association with pelvic fractures. Colonic injury can be particularly difficult to diagnose due to the retroperitoneal location of much of the colon [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22697876\">",
"    <span class=\"h2\">",
"     Penetrating injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any implement or missile that enters the abdomen can injure the bowel. Depending upon the girth of the victim and force applied, even a short implement that penetrates the abdominal wall can cause gastrointestinal injury, particularly in patients with prior abdominal surgery and bowel adhesions.",
"   </p>",
"   <p>",
"    The risk of specific organ injury from penetrating trauma depends upon the instrument used (eg, blunt or sharp), site of penetration, and trajectory and velocity of the missile or object. Gunshot or shotgun wounds are more likely to result in multiple injuries to the hollow viscera compared with stab wounds because of their high energy. A blast injury can also result surrounding the tract of a projectile, particularly when fired from a high velocity weapon. The blast injury can result in devascularization that may evolve over several days to become a perforating wound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H239075955\">",
"    <span class=\"h2\">",
"     Associated injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injuries associated with",
"    <span class=\"nowrap\">",
"     lap/seatbelt",
"    </span>",
"    use, such as flexion-distraction fractures of the spine (Chance fractures) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60907 \" href=\"UTD.htm?42/42/43681\">",
"     image 1",
"    </a>",
"    ), and injury to solid organs (eg, kidney, pancreas) should prompt an evaluation for an associated gastrointestinal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/4-8,11\">",
"     4-8,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42473?source=see_link&amp;anchor=H27#H27\">",
"     \"Spinal column injuries in adults: Definitions, mechanisms, and radiographs\", section on 'Flexion-distraction (lap belt) injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the close anatomic proximity, genitourinary injuries are associated with blunt trauma to the distal colon and upper rectum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18425?source=see_link\">",
"     \"Blunt genitourinary trauma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/32/16904?source=see_link\">",
"     \"Penetrating trauma of the upper and lower genitourinary tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H239075588\">",
"    <span class=\"h1\">",
"     TRAUMA EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;We perform the initial resuscitation, diagnostic evaluation, and management of the patient with blunt or penetrating injury based upon protocols from the Advanced Trauma Life Support (ATLS) program, established by the American College of Surgeons Committee on Trauma. The initial resuscitation and evaluation of the patient with blunt or penetrating abdominal or thoracic trauma is discussed elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link\">",
"       \"Initial evaluation and management of blunt abdominal trauma in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12776?source=see_link\">",
"       \"Initial evaluation and management of abdominal stab wounds in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3943?source=see_link\">",
"       \"Initial evaluation and management of abdominal gunshot wounds in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hemodynamically unstable trauma patients should be transferred immediately to the operating room for evaluation and management. If the clinical setting allows, a Focused Assessment with Sonography for Trauma (FAST) exam or diagnostic peritoneal lavage (DPL) may be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link&amp;anchor=H11#H11\">",
"     \"Initial evaluation and management of blunt abdominal trauma in adults\", section on 'Ultrasound'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link&amp;anchor=H13#H13\">",
"     \"Initial evaluation and management of blunt abdominal trauma in adults\", section on 'Diagnostic peritoneal lavage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      FAST exam &ndash; Although the Focused Assessment with Sonography for Trauma (FAST) serves as a screening tool for the detection of hemoperitoneum in blunt abdominal trauma, FAST is not sensitive for detecting gastrointestinal injury unless there is significant fluid volume of spilled enteric contents from a perforated viscus, or blood from a mesenteric laceration [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]. For patients with blunt abdominal trauma and gastrointestinal injury, the positive predictive value of FAST is low at about 40 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/2\">",
"       2",
"      </a>",
"      ]. Although FAST has little role in the initial evaluation of penetrating abdominal trauma, it may be helpful for decision-making in multi-cavitary penetrating trauma. In a prospective study of 75 consecutive patients with penetrating trauma to the abdomen, flank, or back, the overall sensitivity of FAST was 46 percent, the specificity was 94 percent, and the accuracy was 68 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/15\">",
"       15",
"      </a>",
"      ]. Thus, a negative FAST, particularly if there is a high clinical suspicion of gastrointestinal injury, should be further evaluated using additional imaging, such as a computed tomography or diagnostic peritoneal lavage scan (DPL), or abdominal exploration. (See",
"      <a class=\"local\" href=\"#H239077328\">",
"       'Diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Diagnostic peritoneal lavage &ndash; Diagnostic peritoneal lavage (DPL) is a rapid and inexpensive procedure that may demonstrate spilled intraluminal contents as a result of bowel perforation. With the introduction of FAST and refinements in computed tomography, the indications for DPL have decreased, and, although rarely needed, DPL may be a useful adjunct in patients who do not have indications for immediate intervention [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. When performed, the lavage fluid can be assessed for a white blood cell count (WBC), amylase, and alkaline phosphatase values [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/18-21\">",
"       18-21",
"      </a>",
"      ]. The fluid can also be stained for vegetable fibers, bile, and bacteria to identify contents from a hollow viscus perforation, but the diagnostic utility is low [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/2\">",
"       2",
"      </a>",
"      ]. A positive test (WBC &gt;500",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      alkaline phosphatase level &gt;10",
"      <span class=\"nowrap\">",
"       IU/L,",
"      </span>",
"      amylase level &gt;20",
"      <span class=\"nowrap\">",
"       IU/L,",
"      </span>",
"      or a positive identification of fibers or enteric contents) indicates the need for abdominal exploration. (See",
"      <a class=\"local\" href=\"#H538028240\">",
"       'Approach to management'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H197204297\">",
"       'Abdominal exploration'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H538030155\">",
"    <span class=\"h2\">",
"     History and physical",
"    </span>",
"    &nbsp;&mdash;&nbsp;The trauma history should assess the risk for gastrointestinal injury based upon mechanism. Injury mechanisms associated with gastrointestinal injury are discussed above. (See",
"    <a class=\"local\" href=\"#H533808630\">",
"     'Mechanism of injury'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The trauma patient may complain of abdominal pain, but this symptom is not specific for gastrointestinal injury. Physical examination findings that suggest a possible gastrointestinal injury include abdominal wall ecchymosis, abdominal distention, abdominal tenderness, or signs of peritoneal irritation, but these signs are also not specific for gastrointestinal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/2\">",
"     2",
"    </a>",
"    ]. However, finding no abdominal pain or tenderness significantly decreases the likelihood of finding a gastrointestinal injury that would require surgery. In the Eastern Association for the Surgery of Trauma (EAST) Multi-Institutional Hollow Viscus Injury in Blunt Trauma study, patients with nonperforated small bowel injuries or no small bowel injury were significantly less likely to have abdominal tenderness compared with patients with perforation (53 percent for nonperforated injury, 23 percent no small bowel injury, 72 percent for perforation) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/2\">",
"     2",
"    </a>",
"    ]. Abdominal distention or peritoneal signs were observed in 4 and 10 percent, respectively, of those who did not have gastrointestinal injury. Thus, the majority of patients who do not demonstrate these signs will not have a gastrointestinal injury.",
"   </p>",
"   <p>",
"    A finding of gross blood on digital rectal examination is a sign of possible rectal injury, particularly in patients with open pelvic fractures. A sigmoidoscopy, which is typically performed under anesthesia, is needed to definitively evaluate or exclude this injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H239076452\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific laboratory tests diagnostic for gastrointestinal injury. An initially elevated white blood cell count in the trauma patient is common and frequently related only to the physical stress of trauma. In one study, there were no significant differences in initial red blood cell and white blood cell counts for patients with perforated small bowel injury, nonperforated small bowel injury, or no small bowel injury [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/2\">",
"     2",
"    </a>",
"    ]. However, an increasing or persistently elevated white blood cell count in the patient with abdominal injury may indicate a developing intraabdominal process alerting the clinician to a potential gastrointestinal injury. (See",
"    <a class=\"local\" href=\"#H538028240\">",
"     'Approach to management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H239077328\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definitive diagnosis of traumatic gastrointestinal injury is made at abdominal exploration; however, physical exam and imaging studies, specifically computed tomography (CT) of the abdomen, are important adjuncts that may influence the decision to explore the abdomen.",
"   </p>",
"   <p>",
"    Plain abdominal films may indicate a traumatic gastrointestinal injury overtly as with a finding of pneumoperitoneum (free air), but the trajectory of a missile (ie, gunshot), or presence of a foreign body (eg, bullet, shrapnel) may strongly suggest that a gastrointestinal injury is likely to have occurred. Plain films are not needed if abdominal CT will be performed; however, trajectory mapping may be useful in operative planning or to help determine the need and extent of further imaging.",
"   </p>",
"   <p>",
"    CT of the abdomen is the test of choice for identifying specific intraabdominal injuries in hemodynamically stable patients with blunt injury and is the most sensitive noninvasive imaging test for identifying gastrointestinal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/2,22\">",
"     2,22",
"    </a>",
"    ]. The role of CT scanning in hemodynamically stable patients with suspected penetrating injury is less well-defined. CT may be useful to differentiate patients for whom abdominal exploration is needed from those with injuries that can be appropriately managed nonoperatively, such as patients with a",
"    <span class=\"nowrap\">",
"     low/transpelvic",
"    </span>",
"    trajectory not involving the rectum, a trajectory across the superior abdomen suggestive of an isolated solid organ injury, and possibly those with a lateral trajectory (ie, &ldquo;love handles&rdquo; hit) that may have missed the abdomen altogether. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3943?source=see_link\">",
"     \"Initial evaluation and management of abdominal gunshot wounds in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12776?source=see_link\">",
"     \"Initial evaluation and management of abdominal stab wounds in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Findings on computed tomography (CT) scan that suggest a gastrointestinal injury are listed below [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/22-36\">",
"     22-36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pneumoperitoneum (free, retroperitoneal)",
"     </li>",
"     <li>",
"      Mesenteric air",
"     </li>",
"     <li>",
"      Discontinuity of the hollow viscus wall",
"     </li>",
"     <li>",
"      Extraluminal enteric contrast",
"     </li>",
"     <li>",
"      Free intraabdominal fluid in the absence of solid organ injury",
"     </li>",
"     <li>",
"      Extravasated intravenous contrast",
"     </li>",
"     <li>",
"      Bowel wall thickening or edema",
"     </li>",
"     <li>",
"      Mesenteric hematoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Observational studies report widely disparate efficacies of CT scanning in the diagnosis of blunt intestinal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/2,22,31,32,34,35,37-39\">",
"     2,22,31,32,34,35,37-39",
"    </a>",
"    ]. Some report an accuracy of nearly 100 percent while others have shown that as many as 20 percent of blunt intestinal injuries can be missed by CT. In a systematic review of multidetector CT scan (MDCT) for surgically important bowel",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mesenteric injury after blunt trauma, sensitivities and specificities ranged from 87 to 95 percent and 48 to 84 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/22\">",
"     22",
"    </a>",
"    ]. Various investigators have sought to identify which combinations of CT findings may improve the accuracy of CT scanning for blunt injury, but no sign or combination of signs is infallible, and thus, CT scan findings should always be evaluated in the context of the patient&rsquo;s clinical condition.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the systematic review, the absence of intraperitoneal free fluid on CT scan all but excluded surgically significant injury, while the presence of intraperitoneal free air, vascular beading, abrupt vessel termination, or the presence of extraluminal contrast were highly specific for injury [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective review of 9900 patients with blunt traumatic bowel or mesenteric injuries, the authors noted that the proportion of true positive scans was low in patients with only one positive CT scan finding, but increased significantly with multiple radiographic findings consistent with bowel injury [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the EAST multi-institutional gastrointestinal injury study, gastrointestinal injury was found in 84 percent of patients with free intraabdominal fluid on CT and no evidence of solid organ injury, and in 92 percent of patients with pneumoperitoneum [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/2\">",
"       2",
"      </a>",
"      ]. The presence of free intraabdominal fluid, pneumoperitoneum, or small bowel wall thickening was 75 percent sensitive and 79 percent specific for gastrointestinal injury.",
"     </li>",
"     <li>",
"      By contrast, a multicenter study of 2299 patients with blunt abdominal trauma identified free intraabdominal fluid without solid organ injury on CT scan in 90 patients, and of these, only 8 percent had a gastrointestinal injury identified at laparotomy, indicating that free fluid alone as a CT scan finding should not mandate laparotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/37\">",
"       37",
"      </a>",
"      ]. CT scan detected 22 of 25 blunt intestinal injuries in this series [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/32\">",
"       32",
"      </a>",
"      ]. Abdominal tenderness and bruising were present in 61 percent of all patients, but only 22 percent had a positive CT scan. The negative predictive value of a CT scan was 99.6 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H197204333\">",
"    <span class=\"h1\">",
"     INJURY GRADING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Association for the Surgery of Trauma (AAST) Organ Injury Scales are the most widely used injury classification of traumatic injury including gastrointestinal injury (",
"    <a class=\"graphic graphic_table graphicRef76656 \" href=\"UTD.htm?15/57/16285\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/11,40\">",
"     11,40",
"    </a>",
"    ]. The severity of injury is based upon intraoperative findings",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiographic imaging.",
"   </p>",
"   <p>",
"    Although injury management does not correlate exactly with grade, injury scales provide a practical means to describe the severity of injury and can help guide decisions regarding primary repair",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    resection of gastrointestinal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stomach:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade I &ndash; Intramural hematoma &lt;3 cm; partial-thickness laceration",
"     </li>",
"     <li>",
"      Grade II &ndash; Intramural hematoma &ge;3 cm; full-thickness laceration &lt;3 cm",
"     </li>",
"     <li>",
"      Grade III &ndash; Full-thickness laceration &gt;3 cm",
"     </li>",
"     <li>",
"      Grade IV &ndash; Full-thickness laceration involving vessels on greater",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lesser curvature",
"     </li>",
"     <li>",
"      Grade V &ndash; Extensive rupture &gt;50 percent; devascularization",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Small",
"    <strong>",
"    </strong>",
"    intestine:",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade I &ndash; Contusion or hematoma without devascularization; partial-thickness laceration",
"     </li>",
"     <li>",
"      Grade II &ndash; Full-thickness laceration &lt;50 percent of circumference",
"     </li>",
"     <li>",
"      Grade III &ndash; Full-thickness laceration &ge;50 percent of circumference",
"     </li>",
"     <li>",
"      Grade IV &ndash; Transection",
"     </li>",
"     <li>",
"      Grade V &ndash; Transection with segmental tissue loss; devascularized segment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Colon:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade I &ndash; Contusion or hematoma; partial-thickness laceration",
"     </li>",
"     <li>",
"      Grade II &ndash; Full-thickness laceration &lt;50 percent of circumference",
"     </li>",
"     <li>",
"      Grade III &ndash; Full-thickness laceration &ge;50 percent of circumference",
"     </li>",
"     <li>",
"      Grade IV &ndash; Transection",
"     </li>",
"     <li>",
"      Grade V &ndash; Transection with tissue loss; devascularized segment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rectum and rectosigmoid colon:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade I &ndash; Contusion or hematoma; partial-thickness laceration",
"     </li>",
"     <li>",
"      Grade II &ndash; Full-thickness laceration &lt;50 percent of circumference",
"     </li>",
"     <li>",
"      Grade III &ndash; Full-thickness laceration &ge;50 percent of circumference",
"     </li>",
"     <li>",
"      Grade IV &ndash; Full-thickness laceration with perineal extension",
"     </li>",
"     <li>",
"      Grade V &ndash; Devascularized segment",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H538028240\">",
"    <span class=\"h1\">",
"     APPROACH TO MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with traumatic gastrointestinal injury that is immediately suspected on clinical presentation should undergo abdominal exploration. Absolute indications for immediate operative intervention include hemodynamic instability, diffuse abdominal pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    peritonitis on clinical examination, or findings on initial imaging studies consistent with gastrointestinal perforation (pneumoperitoneum, spilled intraluminal contrast, bowel infarction). In hemodynamically stable patients with abdominal trauma without peritonitis or clear radiographic evidence of gastrointestinal injury, selective nonoperative management is an alternative.",
"   </p>",
"   <p>",
"    For patients with blunt abdominal injury, observational studies support nonoperative management in the setting of a benign abdominal exam and negative or equivocal CT scan findings [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/17,41,42\">",
"     17,41,42",
"    </a>",
"    ]. Mesenteric hematomas identified on CT scan due to blunt injury that are not associated with active contrast extravasation or signs of bowel compromise can also be observed if there are no other operative injuries identified. Many of these hematomas will resorb spontaneously and will not cause any clinical sequelae. However, it is important to note that patients with mesenteric hematoma can develop delayed peritonitis from bowel ischemia that may take several days to develop. Thus, the traditional &ldquo;24 hour&rdquo; observation rule discussed below does not apply to patients with potential devascularization injuries. (See",
"    <a class=\"local\" href=\"#H538028604\">",
"     'Control of mesenteric bleeding'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although less accepted, there is a growing body of evidence to support selective nonoperative management of penetrating abdominal injury. In a large retrospective review, 792 hemodynamically stable patients with abdominal gunshot wounds (no peritoneal signs, reliable clinical examination) were observed with serial abdominal exams and laboratory studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/43\">",
"     43",
"    </a>",
"    ]. Of these, 10 percent developed delayed symptoms requiring laparotomy. The rate of nontherapeutic laparotomy was 14 percent but would have been 47 percent if routine laparotomy had been performed. Complications attributed to delay in operation were observed in 0.3 percent with no increase in mortality. Although the precise duration of observation should be tailored for each individual case based on the clinical course, a minimum observation time of 12 hours for abdominal stab wounds and 24 hours for gunshot wounds in the clinically stable patent has been recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Selective observation of patients with abdominal injury consists of serial abdominal examination, repeat laboratory studies and repeat imaging (usually CT scan), as needed. The main component is frequent serial abdominal examinations, ideally conducted hourly by a member of a dedicated team. For this reason, patients who are unable to provide a reliable physical exam, such as those with coexistent severe brain injury, spinal cord injury, altered mental status, and patients undergoing anesthesia (nonabdominal injury), are not candidates for observation. Clinical signs during the period of observation that suggest the presence of a bowel injury include progressively worsening abdominal pain, hemodynamic instability, or intolerance of oral intake. Monitoring the white cell count may contribute to the clinical picture if significantly or persistently elevated. However, no conclusive data regarding the utility of this parameter exist [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/46\">",
"     46",
"    </a>",
"    ]. White blood cell count should be obtained on admission, and serial counts obtained every six hours until resolution or the need for surgical exploration reveals itself. When indicated, surgical intervention should be undertaken expeditiously to minimize morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/13,47\">",
"     13,47",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H909659935\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When gastrointestinal injury is identified or confirmed at abdominal exploration, the injured bowel can be repaired primarily or resected with an immediate or delayed anastomosis. The choice depends upon the clinical status of the patient, the severity of the specific injury, site of injury, and number and relationship of hollow viscus injuries to each other. The decision also needs to take into account the presence of other traumatic injuries (eg, liver, spleen). At times, a damage control approach may be needed, and is accomplished by quickly securing the injured stomach or bowel to stop bleeding",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gastrointestinal leakage. Definitive repair or resection can be delayed for up to 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H239078037\">",
"    <span class=\"h2\">",
"     Preparation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibiotic prophylaxis &ndash; Prophylactic intravenous antibiotics should be given to all patients who require trauma laparotomy. Antibiotic prophylaxis should be as specific as possible and directed at the site of injury (upper versus lower gastrointestinal tract) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]. However, in patients suspected of having a gastrointestinal injury, the grade and site of injury cannot be known for certain (",
"      <a class=\"graphic graphic_table graphicRef65369 \" href=\"UTD.htm?23/52/24397\">",
"       table 2",
"      </a>",
"      ). If upper and lower tract injuries are suspected, or the site and severity are unknown, broad-spectrum coverage is appropriate. Antibiotic choices are given in the table (",
"      <a class=\"graphic graphic_table graphicRef65369 \" href=\"UTD.htm?23/52/24397\">",
"       table 2",
"      </a>",
"      ) and perioperative coverage is usually sufficient. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"       \"Overview of control measures to prevent surgical site infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18806?source=see_link\">",
"       \"Control measures to prevent surgical site infection following gastrointestinal procedures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thromboprophylaxis &ndash; Patients sustaining trauma are at high risk for deep vein thrombosis and thromboembolism. The choice of prophylaxis depends upon the nature and severity of injuries and the presence of injuries or other conditions that contraindicate their use. Therapies for the prevention of deep vein thrombosis and pulmonary embolism are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31066?source=see_link&amp;anchor=H172458244#H172458244\">",
"       \"Overview of inpatient management in the adult trauma patient\", section on 'Thromboprophylaxis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H197204297\">",
"    <span class=\"h2\">",
"     Abdominal exploration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodynamically unstable patients and those with multiple injuries should be explored though a generous midline abdominal incision. Trauma laparotomy should be performed in a standard fashion by packing the four quadrants and evaluating the intraabdominal organs in a systematic fashion, and when indicated, exploring the retroperitoneum.",
"   </p>",
"   <p>",
"    Although laparoscopy is a safe and effective diagnostic tool that has become commonplace in general surgery, it is uncommonly needed in the setting of trauma but can be useful for evaluating diaphragmatic lacerations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28009?source=see_link\">",
"     \"Recognition and management of diaphragmatic injury in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laparoscopy in the evaluation of hemodynamically stable patients with abdominal trauma has been primarily applied to those with penetrating trauma to evaluate whether peritoneal penetration has occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. However, we do not generally advocate this approach. For appropriate candidates in whom reliable serial abdominal examinations can be performed, we prefer selective, nonoperative management. (See",
"    <a class=\"local\" href=\"#H538028240\">",
"     'Approach to management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In accordance with accepted trauma protocols, injuries to the gastrointestinal tract should be evaluated and repaired in a systematic manner. Control of intraabdominal hemorrhage (spleen, liver, mesentery) should be the first priority to minimize the need for transfusion and minimize fluid requirements [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/57\">",
"     57",
"    </a>",
"    ], followed by control of gastrointestinal contamination [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients who are hemodynamically stable with limited other injuries can undergo definitive management of their bowel injuries at the time of the initial exploration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. In the setting of damage control, repair of gastrointestinal injury should be delayed until after hemodynamic stabilization, which is typically within 24 hours of the injury. Repair should be undertaken no later than 48 to 72 hours after injury because bowel distention can extend the injury.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The anterior and posterior surfaces of the stomach should be inspected for signs of contusion or laceration. The posterior surface can be examined after opening the lesser sac. Ligating a few of the short gastric arteries will facilitate exposure. Small gastric perforations can be identified by injecting air into the nasogastric tube to insufflate the stomach and then filling the abdomen with saline to cover the stomach while observing for air bubbles. Alternatively,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"       methylene blue",
"      </a>",
"      can be instilled into the stomach via the nasogastric tube and the stomach inspected for leakage.",
"     </li>",
"     <li>",
"      The entire bowel and mesentery, beginning from the ligament of Treitz, should be examined. All abnormalities should be thoroughly evaluated and tagged (eg, bowel clamp), but definitive repair should not be undertaken until the entire length of bowel has been examined. (See",
"      <a class=\"local\" href=\"#H791235263\">",
"       'Management of intestinal injuries'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Evaluation of duodenal injury requires mobilizing the duodenum from its retroperitoneal attachments, and the pancreas, which is commonly injured as well, should also be examined. Duodenal and pancreatic injuries are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22266?source=see_link\">",
"       \"Management of duodenal and pancreatic trauma in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If there is evidence of large bowel injury (eg, overlying hematoma), the involved region of the colon should be fully mobilized to allow inspection of the colon circumferentially.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H538028604\">",
"    <span class=\"h2\">",
"     Control of mesenteric bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesenteric bleeding and mesenteric hematomas identified intraoperatively can be managed using straightforward techniques. Active mesenteric arterial bleeding can usually be controlled with simple ligation. Due to the rich collateral blood supply to most areas of the small intestine, limited ligation of mesenteric arterial vessels will not result in bowel compromise, but multiple ligations, proximal arterial branch ligation (",
"    <a class=\"graphic graphic_figure graphicRef85571 \" href=\"UTD.htm?37/19/38197\">",
"     figure 2",
"    </a>",
"    ), or mesenteric resection may necessitate resection of the associated bowel. Once the injury to the mesentery has been managed, the viability of the bowel should be assessed. (See",
"    <a class=\"local\" href=\"#H791235395\">",
"     'Evaluating bowel viability'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most mesenteric venous injuries can be ligated without sequelae. Although ligation of the inferior mesenteric vein is well tolerated, the superior mesenteric vein (SMV) should be preserved whenever possible. If ligation of the SMV is necessary, the surgeon should consider temporary abdominal closure and &ldquo;second look operation&rdquo; given the potential for massive bowel edema. (See",
"    <a class=\"local\" href=\"#H538030097\">",
"     'Abdominal closure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H791235395\">",
"    <span class=\"h2\">",
"     Evaluating bowel viability",
"    </span>",
"    &nbsp;&mdash;&nbsp;The integrity of the bowel should be carefully inspected, particularly in areas of mesenteric injury. Areas of bowel for which the viability is uncertain should be observed throughout the course of the operation. A warm (not hot) laparotomy pad can be placed over the region to promote blood flow. The patient&rsquo;s hemodynamic status should be reevaluated and hypotension corrected, avoiding vasoconstricting agents if possible.",
"   </p>",
"   <p>",
"    Bowel viability is generally assessed in the operating room using a combination of clinical experience and judgement, a handheld continuous wave Doppler to assess for audible arterial signals within the mesentery and bowel wall, and intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    administration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/60-66\">",
"     60-66",
"    </a>",
"    ]. Within a few minutes of giving fluorescein (1 to 2 ampules, 500 mg each), examination of the bowel with ultraviolet light (ie, Woods lamp) will show perfused regions as bright green while areas of ischemia will appear darker by comparison. If warming and improvement in the patient&rsquo;s blood pressure do not improve intestinal perfusion, resection of the affected segment may be required. Areas of bowel that are potentially viable should not be resected immediately; rather, a second-look operation should be planned for no later than 24 hours after the initial procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H791235263\">",
"    <span class=\"h2\">",
"     Management of intestinal injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether a specific injury should be repaired or resected depends upon the grade of bowel injury (",
"    <a class=\"graphic graphic_table graphicRef76656 \" href=\"UTD.htm?15/57/16285\">",
"     table 1",
"    </a>",
"    ), the presence of other closely associated hollow viscus injuries, the adequacy of perfusion to the segment of bowel, and the patient&rsquo;s overall clinical status. Immediate resection is indicated for overtly infarcted segments of bowel and devascularized bowel segments. Resection is frequently necessary for multiple injuries affecting the same bowel segment. Resected segments of stomach, small bowel, colon, and intraperitoneal rectum can be reapproximated primarily without proximal diversion (ostomy creation) under most circumstances. For patients with severe and multiple injuries, a damage-control approach involves resecting the affected segments of bowel using a gastrointestinal stapler, and delaying restoration of gastrointestinal continuity until the patient has stabilized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70383561\">",
"    <span class=\"h3\">",
"     Repair techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options for intestinal repair include using a one-layer or two-layer hand-sewn technique or a stapled technique. The choice of technique depends upon the location of the injury, the nature and extent of the patient&rsquo;s other injuries, and surgeon experience and preference.",
"   </p>",
"   <p>",
"    A stapled technique can be liberally applied to small and large bowel anastomoses when managing traumatic gastrointestinal injuries when there is a minimal size discrepancy between the ends of the bowel. Hand-sewn and stapled techniques have been shown in observational studies to have similar complication rates (eg, anastomotic leak, infection) in the trauma population [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/67-71\">",
"     67-71",
"    </a>",
"    ]. However, it is important to remember that bowel edema from the traumatic injury can prevent proper closure with a gastrointestinal stapler [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The stomach is highly vascular and is usually closed using two layers to provide better hemostasis. In a two-layer closure, the inner layer is a running, absorbable suture and the outer layer is interrupted, permanent (eg, silk), Lembert sutures. An alternative to a hand-sewn closure for a gastric laceration is closure using a gastrointestinal anastomosis (GIA) stapler.",
"   </p>",
"   <p>",
"    Intestinal anastomoses can be performed using a one-layer or two-layer hand-sewn or stapled technique. Single-layer hand-sewn anastomosis is constructed using a running 3-0 permanent (eg, polypropylene) suture while the two-layer technique uses a running, absorbable suture for the inner layer and interrupted, permanent (eg, silk) Lembert sutures for the outer layer. In a randomized trial of 125 patients undergoing elective surgery, no differences in complication rates or lengths of hospital stay were found for a one-layer versus a two-layer technique for intestinal anastomosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70383435\">",
"    <span class=\"h3\">",
"     Repair by injury grade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low grade injuries (grade I, II, or III) (",
"    <a class=\"graphic graphic_table graphicRef76656 \" href=\"UTD.htm?15/57/16285\">",
"     table 1",
"    </a>",
"    ) of the stomach, small bowel, colon, and rectum can usually be repaired primarily, whereas higher grade injuries are generally not amenable to primary repair, and will require resection. Techniques for intestinal repair are discussed elsewhere. (See",
"    <a class=\"local\" href=\"#H70383561\">",
"     'Repair techniques'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade I &ndash; Partial-thickness lacerations should be repaired primarily in one or two layers. Intramural hematomas encountered intraoperatively are typically opened, evacuated, and the bowel wall inspected and repaired. The management of duodenal hematomas is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22266?source=see_link\">",
"       \"Management of duodenal and pancreatic trauma in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Grade II &ndash; The edges of small, full-thickness lacerations should be debrided to fresh margins and repaired as discussed above. Small bowel defects should be closed transversely (aligned with",
"      <span class=\"nowrap\">",
"       mesenteric/antimesenteric",
"      </span>",
"      axis) to avoid narrowing the lumen or compromising bowel vascularity.",
"     </li>",
"     <li>",
"      Grade III &ndash; Many larger lacerations of the small bowel, colon, and rectum can also be repaired with debridement and primary closure. However, lacerations located in certain regions require a more specific approach.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A gastric laceration near the pylorus should be repaired transversely, such as when performing a pyloroplasty, to maintain a wide gastric outlet.",
"     </li>",
"     <li>",
"      An injury at the gastroesophageal junction should be repaired in one or two layers over a nasogastric tube with closed-suction drainage and consideration of a fundoplication to buttress the repair.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade IV and V &ndash; Extensive injury or devascularized segments of small or large bowel require resection and anastomosis as appropriate. Such injuries to the stomach",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      duodenum often require complex repair or reconstruction depending upon the location and extent of injury as well as the patient&rsquo;s overall clinical status. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22266?source=see_link\">",
"       \"Management of duodenal and pancreatic trauma in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H629604702\">",
"    <span class=\"h3\">",
"     Colorectal injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following debridement or resection, observational studies comparing outcomes for colorectal repair with historical controls that favored ostomy creation support primary repair or primary anastomosis for the majority of colorectal injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/73-78\">",
"     73-78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with nondestructive colon and intraperitoneal rectal injuries, primary closure is associated with fewer complications [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/73\">",
"     73",
"    </a>",
"    ]. For colon injuries not amenable to primary repair, colon resection with primary anastomosis can be performed in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/73-78\">",
"     73-78",
"    </a>",
"    ]. Risk factors that have previously been associated with breakdown of colon repairs have included significant comorbid conditions, &gt;6 units of blood transfusion, shock, delay in operation, and heavy fecal contamination [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. However, a prospective, multicenter trial undertaken by the American Association for Surgery in Trauma (AAST) that included 297 patients found that the surgical method of colon repair did not influence the rate of abdominal complications, irrespective of associated risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For extraperitoneal rectal injuries, diverting colostomy alone may be adequate for managing penetrating rectal injury (missile, penetrating bony fragment), which has traditionally been managed with primary repair, presacral drainage, rectal washout, and proximal diversion (colostomy) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. In one small trial of 48 patients with penetrating rectal injuries, no differences in outcome were found whether or not presacral drainage was used [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H538030097\">",
"    <span class=\"h2\">",
"     Abdominal closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following trauma surgery, a decision to close the abdomen with or without skin closure depends upon the ability to approximate the fascial edges, the amount of intraabdominal contamination, the potential for anastomotic breakdown, and the need to perform a second-look operation. In patients undergoing damage control surgery and in those with a planned second-look operation to assess bowel viability, the abdomen should be left open and a temporary abdominal closure used. Leaving the abdomen open may also be more prudent in patients who are at risk for abdominal compartment syndrome. Methods of diagnosing abdominal compartment syndrome and the management of the open abdomen are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link\">",
"     \"Abdominal compartment syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1097?source=see_link\">",
"     \"Management of the open abdomen in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the abdominal fascia is closed, the question of whether to close the skin is unresolved. A randomized trial of 48 patients with colon injuries found that leaving the skin wound open resulted in significantly fewer wound infections compared with skin wound closure (17 versus 31 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/81\">",
"     81",
"    </a>",
"    ]. Thus, with injury to the colon, rectum, or in cases of a large volume of material spilled from the stomach or small bowel, we prefer to loosely approximate the skin edges with staples, which can be easily removed should an infection become apparent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H791235782\">",
"    <span class=\"h3\">",
"     Role of drains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are limited regarding the use of intraabdominal drains in emergency trauma surgery. Extrapolating from data obtained in elective surgery, we prefer not to use drains following repair or resection of most gastrointestinal injuries. One notable exception is stomach injuries requiring total gastrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/82\">",
"     82",
"    </a>",
"    ]. Although the systematic review identified no specific data, expert consensus concluded that drains should be used following total gastrectomy with esophageal-jejunal anastomosis because of the high mortality rates associated with anastomotic leak [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/83\">",
"     83",
"    </a>",
"    ]. Thus, in the setting of an emergent total gastrectomy with an esophageal anastomosis, we prophylactically drain the repair site.",
"   </p>",
"   <p>",
"    In elective surgery, drainage of colorectal anastomoses does not influence postoperative morbidity (eg, surgical site infections) or mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/76,78,83-88\">",
"     76,78,83-88",
"    </a>",
"    ]. A systematic review identified eight trials (two emergency surgery), that compared drainage following colorectal resections (primary anastomosis) with no drainage. No significant differences were found in the incidence of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/83\">",
"     83",
"    </a>",
"    ]. Thus, we prefer not to use drains following the repair or resection of colon or intraperitoneal rectum when managing traumatic injury. [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/83\">",
"     83",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H538035352\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperatively, the patient is typically cared for in an intensive care unit unless an isolated bowel injury has been repaired. General issues related to the inpatient care of injured patients are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31066?source=see_link\">",
"     \"Overview of inpatient management in the adult trauma patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with rectal injury who required a diverting colostomy should have frequent evaluations of the ostomy site to ensure viability. The routine care and management of colostomies are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2218?source=see_link\">",
"       \"Management of patients with a colostomy or ileostomy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have undergone abdominal wall closure, we have a low threshold to monitor intraabdominal pressure. The diagnosis of abdominal compartment syndrome and indications for abdominal decompression are reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link&amp;anchor=H20#H20\">",
"       \"Abdominal compartment syndrome\", section on 'Measurement of intraabdominal pressure'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The open abdomen is managed with a temporary abdominal closure. The frequency of dressing changes depends upon the intraabdominal injuries and type of closure used. An ostomy can interfere with the temporary abdominal closure device, and alternative techniques for placement might need to be considered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1097?source=see_link\">",
"       \"Management of the open abdomen in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1097?source=see_link&amp;anchor=H255251544#H255251544\">",
"       \"Management of the open abdomen in adults\", section on 'Ostomy placement'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75801689\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following management of gastrointestinal injury, the incidence of complications ranges from 22 to 29 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/2,75\">",
"     2,75",
"    </a>",
"    ]. Common postoperative complications include systemic complications such as pneumonia, sepsis, and renal dysfunction and thromboembolism, and complications specific to abdominal surgery such as surgical site infection, intraabdominal abscess, and abdominal sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/10,13,89\">",
"     10,13,89",
"    </a>",
"    ]. A multivariate analysis of 102 patients with traumatic bowel injury (all mechanisms) identified time to surgery and colon injury as independent risk factors for morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the EAST multi-institutional gastrointestinal injury study, the incidence of complications in patients suffering blunt abdominal trauma with small bowel injury was significantly higher compared with those who did not have small bowel injury (29 versus 13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/2\">",
"     2",
"    </a>",
"    ]. A delay in diagnosis of small bowel injury &gt;24 hours was associated with a significantly higher morbidity rate compared with a diagnosis made within 8 hours (55 versus 8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/2\">",
"     2",
"    </a>",
"    ]. The exact time cutoff for increased morbidity (and mortality) is unknown.",
"   </p>",
"   <p>",
"    Surgical site infection is common in patients with gastrointestinal injury. In one review, surgical site infection occurred in 14 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/91\">",
"     91",
"    </a>",
"    ]. In a prospective study of 178 patients with penetrating abdominal injury, the overall incidence of surgical site infection (SSI) (wound infection, fascial dehiscence, or intraabdominal abscess) was 20 percent and the incidence of enterocutaneous fistula was 3.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/89\">",
"     89",
"    </a>",
"    ]. Risk factors for SSI included duodenal and colonic injuries. When patients with colon injuries were excluded, the SSI was 16 percent for patients with gastric injuries and 13 percent for those with small bowel injuries. In contrast to the EAST study [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], there was no association between SSI and time to operative management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75801954\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality in patients with gastrointestinal injury is related to overall injury severity (ISS) score, associated solid organ and vascular injuries, and medical comorbidities. Mortality related directly to the gastrointestinal injury is most closely related to a delay in initial diagnosis, intraabdominal sepsis, and development of multiorgan failure. In a retrospective review of 268 patients with gastrointestinal injury, mortality rates were 28 percent for injuries to the stomach, 19 percent for rectal injuries, and 15 percent for small bowel injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mortality rates for patients sustaining a ruptured stomach have been reported between 28 and 66 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/1,2,8\">",
"     1,2,8",
"    </a>",
"    ]. The higher mortality rate for stomach injury appeared to be related to the more severe injury mechanism needed to cause gastric perforation, and multiple other associated organ injuries (eg, spleen, diaphragm, lung), as evidenced by higher mean injury severity scores [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A delay in diagnosis &ge;24 hours in patients found to have isolated blunt small bowel injury was associated with a significantly higher mortality compared with diagnosis at &lt;24 hours (16 versus 4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/2\">",
"     2",
"    </a>",
"    ]. In the EAST Hollow Viscus Injury in Blunt Trauma Study, patients with small bowel injury were significantly more likely to die compared with patients sustaining blunt abdominal trauma who did not have small bowel injury (19 versus 14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multicenter study of patients who survived the first 72 hours after penetrating colon injury found an overall colon-injury-related mortality rate of 1.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/57/26522/abstract/75\">",
"     75",
"    </a>",
"    ]. All the patients who died were treated with a proximal diversion at the time of initial procedure, and death was ultimately the result of intraabdominal sepsis and multiorgan failure. The need for colostomy is a marker of severe injury. (See",
"    <a class=\"local\" href=\"#H75801689\">",
"     'Complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H909660042\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastrointestinal injury refers to injury of the stomach, small bowel, colon, or rectum due to traumatic mechanisms, which can be blunt or penetrating. Gastrointestinal injury is less common than solid organ injury and occurs more often following penetrating than blunt trauma. The nature and severity of the injury depends upon the injury mechanism, with injuries ranging from minor bruising to complete devascularization. (See",
"      <a class=\"local\" href=\"#H1065773\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical evaluation of the trauma patient should assess the risk for gastrointestinal injury based upon injury mechanism. Although physical examination findings (eg, wall ecchymosis, abdominal distention, abdominal tenderness, or signs of peritoneal irritation) may suggest intraabdominal injury, these signs are not specific for gastrointestinal injury. (See",
"      <a class=\"local\" href=\"#H239075588\">",
"       'Trauma evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In conjunction with physical examination, computed tomography (CT) is the test of choice for identifying specific intraabdominal injuries in the hemodynamically stable trauma patient, and is the most sensitive noninvasive test for identifying gastrointestinal injury. Findings on CT scan that suggest a gastrointestinal injury include free air (pneumoperitoneum), mesenteric air, extraluminal enteric contrast, discontinuity of the wall of a hollow viscus, free intraabdominal fluid in the absence of solid organ injury, bowel wall thickening, active bleeding (extravasated intravenous contrast), evidence of bowel infarct, and mesenteric hematoma. A diagnostic peritoneal lavage (DPL) may be useful if CT scan is equivocal, but, ultimately, abdominal exploration is required to establish the diagnosis. (See",
"      <a class=\"local\" href=\"#H239077328\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with abdominal trauma who are hemodynamically unstable, patients with known gastrointestinal injury, and those with other abdominal injuries that require operative intervention should be taken to the operating room for open abdominal exploration. Observation may be appropriate for selected hemodynamically stable patients in the absence of peritonitis when no other operative injuries are present, imaging studies are equivocal for gastrointestinal injury, and a reliable physical exam is possible. Mesenteric and intramural hematomas can resolve without the need for surgery. (See",
"      <a class=\"local\" href=\"#H538028240\">",
"       'Approach to management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We use the American Association for the Surgery of Trauma (AAST) Organ Injury system to grade gastrointestinal injuries based upon CT findings or findings in the operating room. Grading can help guide surgical management of the injury. A damage control approach to bowel injury may be needed when severe associated injuries are present, and is accomplished by quickly securing the injured stomach or bowel to stop bleeding",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gastrointestinal leakage. Definitive repair or resection can be delayed for up to 24 hours. (See",
"      <a class=\"local\" href=\"#H909659935\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The decision to perform a primary repair or resect injured bowel depends upon the severity and location of the injury, and proximity of the injuries to each other. Grade I, II, and III injuries of the stomach, small bowel, colon, and rectum can usually be repaired primarily; however, multiple injuries along the same segment or higher-grade injuries (Grade IV, V) typically need resection. (See",
"      <a class=\"local\" href=\"#H197204333\">",
"       'Injury grading'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H791235263\">",
"       'Management of intestinal injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with colon or intraperitoneal rectal injuries, we suggest primary repair, or resection and re-anastomosis (as appropriate), but without a diverting colostomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For most patients with extraperitoneal rectal injuries, proximal diverting colostomy alone is sufficient. (See",
"      <a class=\"local\" href=\"#H629604702\">",
"       'Colorectal injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients undergoing total gastrectomy for trauma, we suggest the placement of an intraabdominal drain at the esophagojejunal anastomosis rather than no drainage (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For other gastrointestinal injuries, we suggest not placing drains following repair or resection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H791235782\">",
"       'Role of drains'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following exploratory laparotomy for trauma, the abdominal wall may need to remain open because of the risk for abdominal compartment syndrome, or the need for a planned second-look procedure (damage control). (See",
"      <a class=\"local\" href=\"#H538030097\">",
"       'Abdominal closure'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1097?source=see_link\">",
"       \"Management of the open abdomen in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/1\">",
"      Watts DD, Fakhry SM, EAST Multi-Institutional Hollow Viscus Injury Research Group. Incidence of hollow viscus injury in blunt trauma: an analysis from 275,557 trauma admissions from the East multi-institutional trial. J Trauma 2003; 54:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/2\">",
"      Fakhry SM, Watts DD, Luchette FA, EAST Multi-Institutional Hollow Viscus Injury Research Group. Current diagnostic approaches lack sensitivity in the diagnosis of perforated blunt small bowel injury: analysis from 275,557 trauma admissions from the EAST multi-institutional HVI trial. J Trauma 2003; 54:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/3\">",
"      Guarino J, Hassett JM Jr, Luchette FA. Small bowel injuries: mechanisms, patterns, and outcome. J Trauma 1995; 39:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/4\">",
"      Bruscagin V, Coimbra R, Rasslan S, et al. Blunt gastric injury. A multicentre experience. Injury 2001; 32:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/5\">",
"      Nance ML, Peden GW, Shapiro MB, et al. Solid viscus injury predicts major hollow viscus injury in blunt abdominal trauma. J Trauma 1997; 43:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/6\">",
"      Ishikawa K, Ueda Y, Sonoda K, et al. Multiple gastric ruptures caused by blunt abdominal trauma: report of a case. Surg Today 2002; 32:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/7\">",
"      Tejerina Alvarez EE, Holanda MS, L&oacute;pez-Espadas F, et al. Gastric rupture from blunt abdominal trauma. Injury 2004; 35:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/8\">",
"      Oncel D, Malinoski D, Brown C, et al. Blunt gastric injuries. Am Surg 2007; 73:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/9\">",
"      Frick EJ Jr, Pasquale MD, Cipolle MD. Small-bowel and mesentery injuries in blunt trauma. J Trauma 1999; 46:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/10\">",
"      Williams MD, Watts D, Fakhry S. Colon injury after blunt abdominal trauma: results of the EAST Multi-Institutional Hollow Viscus Injury Study. J Trauma 2003; 55:906.",
"     </a>",
"    </li>",
"    <li>",
"     Weinberg JA, Fabian TC. Chapter 8: Injuries to the stomach, small bowel, colon, and rectum. In: ACS Surgery: Principles and Practice.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/12\">",
"      Brown MA, Sirlin CB, Hoyt DB, Casola G. Screening ultrasound in blunt abdominal trauma. J Intensive Care Med 2003; 18:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/13\">",
"      Fakhry SM, Brownstein M, Watts DD, et al. Relatively short diagnostic delays (&lt;8 hours) produce morbidity and mortality in blunt small bowel injury: an analysis of time to operative intervention in 198 patients from a multicenter experience. J Trauma 2000; 48:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/14\">",
"      Lorente-Ramos RM, Santiago-Hernando A, Del Valle-Sanz Y, Arjonilla-Lopez A. Sonographic diagnosis of intramural duodenal hematomas. J Clin Ultrasound 1999; 27:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/15\">",
"      Udobi KF, Rodriguez A, Chiu WC, Scalea TM. Role of ultrasonography in penetrating abdominal trauma: a prospective clinical study. J Trauma 2001; 50:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/16\">",
"      Wang YC, Hsieh CH, Fu CY, et al. Hollow organ perforation in blunt abdominal trauma: the role of diagnostic peritoneal lavage. Am J Emerg Med 2012; 30:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/17\">",
"      Baron BJ, Scalea TM, Sclafani SJ, et al. Nonoperative management of blunt abdominal trauma: the role of sequential diagnostic peritoneal lavage, computed tomography, and angiography. Ann Emerg Med 1993; 22:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/18\">",
"      Sriussadaporn S, Pak-art R, Pattaratiwanon M, et al. Clinical uses of diagnostic peritoneal lavage in stab wounds of the anterior abdomen: a prospective study. Eur J Surg 2002; 168:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/19\">",
"      Nagy KK, Roberts RR, Joseph KT, et al. Experience with over 2500 diagnostic peritoneal lavages. Injury 2000; 31:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/20\">",
"      Feliciano DV, Bitondo-Dyer CG. Vagaries of the lavage white blood cell count in evaluating abdominal stab wounds. Am J Surg 1994; 168:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/21\">",
"      Henneman PL, Marx JA, Moore EE, et al. Diagnostic peritoneal lavage: accuracy in predicting necessary laparotomy following blunt and penetrating trauma. J Trauma 1990; 30:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/22\">",
"      Atri M, Hanson JM, Grinblat L, et al. Surgically important bowel and/or mesenteric injury in blunt trauma: accuracy of multidetector CT for evaluation. Radiology 2008; 249:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/23\">",
"      Scaglione M, de Lutio di Castelguidone E, Scialpi M, et al. Blunt trauma to the gastrointestinal tract and mesentery: is there a role for helical CT in the decision-making process? Eur J Radiol 2004; 50:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/24\">",
"      Kim HC, Shin HC, Park SJ, et al. Traumatic bowel perforation: analysis of CT findings according to the perforation site and the elapsed time since accident. Clin Imaging 2004; 28:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/25\">",
"      Hanks PW, Brody JM. Blunt injury to mesentery and small bowel: CT evaluation. Radiol Clin North Am 2003; 41:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/26\">",
"      Brofman N, Atri M, Hanson JM, et al. Evaluation of bowel and mesenteric blunt trauma with multidetector CT. Radiographics 2006; 26:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/27\">",
"      Miki T, Ogata S, Uto M, et al. Multidetector-row CT findings of colonic perforation: direct visualization of ruptured colonic wall. Abdom Imaging 2004; 29:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/28\">",
"      Drasin TE, Anderson SW, Asandra A, et al. MDCT evaluation of blunt abdominal trauma: clinical significance of free intraperitoneal fluid in males with absence of identifiable injury. AJR Am J Roentgenol 2008; 191:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/29\">",
"      Yu J, Fulcher AS, Wang DB, et al. Frequency and importance of small amount of isolated pelvic free fluid detected with multidetector CT in male patients with blunt trauma. Radiology 2010; 256:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/30\">",
"      Butela ST, Federle MP, Chang PJ, et al. Performance of CT in detection of bowel injury. AJR Am J Roentgenol 2001; 176:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/31\">",
"      Malhotra AK, Fabian TC, Katsis SB, et al. Blunt bowel and mesenteric injuries: the role of screening computed tomography. J Trauma 2000; 48:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/32\">",
"      Livingston DH, Lavery RF, Passannante MR, et al. Admission or observation is not necessary after a negative abdominal computed tomographic scan in patients with suspected blunt abdominal trauma: results of a prospective, multi-institutional trial. J Trauma 1998; 44:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/33\">",
"      LeBedis CA, Anderson SW, Soto JA. CT imaging of blunt traumatic bowel and mesenteric injuries. Radiol Clin North Am 2012; 50:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/34\">",
"      Wu CH, Wang LJ, Wong YC, et al. Contrast-enhanced multiphasic computed tomography for identifying life-threatening mesenteric hemorrhage and transmural bowel injuries. J Trauma 2011; 71:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/35\">",
"      Tan KK, Liu JZ, Go TS, et al. Computed tomography has an important role in hollow viscus and mesenteric injuries after blunt abdominal trauma. Injury 2010; 41:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/36\">",
"      Bhagvan S, Turai M, Holden A, et al. Predicting hollow viscus injury in blunt abdominal trauma with computed tomography. World J Surg 2013; 37:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/37\">",
"      Livingston DH, Lavery RF, Passannante MR, et al. Free fluid on abdominal computed tomography without solid organ injury after blunt abdominal injury does not mandate celiotomy. Am J Surg 2001; 182:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/38\">",
"      Menegaux F, Tr&eacute;sallet C, Gosgnach M, et al. Diagnosis of bowel and mesenteric injuries in blunt abdominal trauma: a prospective study. Am J Emerg Med 2006; 24:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/39\">",
"      Elton C, Riaz AA, Young N, et al. Accuracy of computed tomography in the detection of blunt bowel and mesenteric injuries. Br J Surg 2005; 92:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/40\">",
"      Moore EE, Cogbill TH, Malangoni MA, et al. Organ injury scaling, II: Pancreas, duodenum, small bowel, colon, and rectum. J Trauma 1990; 30:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/41\">",
"      Yegiyants S, Abou-Lahoud G, Taylor E. The management of blunt abdominal trauma patients with computed tomography scan findings of free peritoneal fluid and no evidence of solid organ injury. Am Surg 2006; 72:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/42\">",
"      DeMaria EJ. Management of patients with indeterminate diagnostic peritoneal lavage results following blunt trauma. J Trauma 1991; 31:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/43\">",
"      Velmahos GC, Demetriades D, Toutouzas KG, et al. Selective nonoperative management in 1,856 patients with abdominal gunshot wounds: should routine laparotomy still be the standard of care? Ann Surg 2001; 234:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/44\">",
"      Inaba K, Branco BC, Moe D, et al. Prospective evaluation of selective nonoperative management of torso gunshot wounds: when is it safe to discharge? J Trauma Acute Care Surg 2012; 72:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/45\">",
"      Alzamel HA, Cohn SM. When is it safe to discharge asymptomatic patients with abdominal stab wounds? J Trauma 2005; 58:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/46\">",
"      Schn&uuml;riger B, Inaba K, Barmparas G, et al. Serial white blood cell counts in trauma: do they predict a hollow viscus injury? J Trauma 2010; 69:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/47\">",
"      Malinoski DJ, Patel MS, Yakar DO, et al. A diagnostic delay of 5 hours increases the risk of death after blunt hollow viscus injury. J Trauma 2010; 69:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/48\">",
"      Schreiber MA. Damage control surgery. Crit Care Clin 2004; 20:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/49\">",
"      Kirton OC, O'Neill PA, Kestner M, Tortella BJ. Perioperative antibiotic use in high-risk penetrating hollow viscus injury: a prospective randomized, double-blind, placebo-control trial of 24 hours versus 5 days. J Trauma 2000; 49:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/50\">",
"      Goldberg SR, Anand RJ, Como JJ, et al. Prophylactic antibiotic use in penetrating abdominal trauma: an Eastern Association for the Surgery of Trauma practice management guideline. J Trauma Acute Care Surg 2012; 73:S321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/51\">",
"      Ortega AE, Tang E, Froes ET, et al. Laparoscopic evaluation of penetrating thoracoabdominal traumatic injuries. Surg Endosc 1996; 10:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/52\">",
"      Murray JA, Demetriades D, Asensio JA, et al. Occult injuries to the diaphragm: prospective evaluation of laparoscopy in penetrating injuries to the left lower chest. J Am Coll Surg 1998; 187:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/53\">",
"      O'Malley E, Boyle E, O'Callaghan A, et al. Role of laparoscopy in penetrating abdominal trauma: a systematic review. World J Surg 2013; 37:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/54\">",
"      Como JJ, Bokhari F, Chiu WC, et al. Practice management guidelines for selective nonoperative management of penetrating abdominal trauma. J Trauma 2010; 68:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/55\">",
"      Johnson JJ, Garwe T, Raines AR, et al. The use of laparoscopy in the diagnosis and treatment of blunt and penetrating abdominal injuries: 10-year experience at a level 1 trauma center. Am J Surg 2013; 205:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/56\">",
"      Lee PC, Lo C, Wu JM, et al. Laparoscopy Decreases the Laparotomy Rate in Hemodynamically Stable Patients With Blunt Abdominal Trauma. Surg Innov 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/57\">",
"      Cotton BA, Reddy N, Hatch QM, et al. Damage control resuscitation is associated with a reduction in resuscitation volumes and improvement in survival in 390 damage control laparotomy patients. Ann Surg 2011; 254:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/58\">",
"      Ordo&ntilde;ez CA, Pino LF, Badiel M, et al. Safety of performing a delayed anastomosis during damage control laparotomy in patients with destructive colon injuries. J Trauma 2011; 71:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/59\">",
"      Burlew CC, Moore EE, Cuschieri J, et al. Sew it up! A Western Trauma Association multi-institutional study of enteric injury management in the postinjury open abdomen. J Trauma 2011; 70:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/60\">",
"      Bulkley GB, Zuidema GD, Hamilton SR, et al. Intraoperative determination of small intestinal viability following ischemic injury: a prospective, controlled trial of two adjuvant methods (Doppler and fluorescein) compared with standard clinical judgment. Ann Surg 1981; 193:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/61\">",
"      Urbanaviius L, Pattyn P, de Putte DV, Venskutonis D. How to assess intestinal viability during surgery: A review of techniques. World J Gastrointest Surg 2011; 3:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/62\">",
"      Ballard JL, Stone WM, Hallett JW, et al. A critical analysis of adjuvant techniques used to assess bowel viability in acute mesenteric ischemia. Am Surg 1993; 59:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/63\">",
"      Ando M, Ito M, Nihei Z, Sugihara K. Assessment of intestinal viability using a non-contact laser tissue blood flowmeter. Am J Surg 2000; 180:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/64\">",
"      Horgan PG, Gorey TF. Operative assessment of intestinal viability. Surg Clin North Am 1992; 72:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/65\">",
"      Locke R, Hauser CJ, Shoemaker WC. The use of surface oximetry to assess bowel viability. Arch Surg 1984; 119:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/66\">",
"      O'Donnell JA, Hobson RW 2nd. Operative confirmation of Doppler ultrasound in evaluation of intestinal ischemia. Surgery 1980; 87:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/67\">",
"      Brundage SI, Jurkovich GJ, Grossman DC, et al. Stapled versus sutured gastrointestinal anastomoses in the trauma patient. J Trauma 1999; 47:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/68\">",
"      Witzke JD, Kraatz JJ, Morken JM, et al. Stapled versus hand sewn anastomoses in patients with small bowel injury: a changing perspective. J Trauma 2000; 49:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/69\">",
"      Brundage SI, Jurkovich GJ, Hoyt DB, et al. Stapled versus sutured gastrointestinal anastomoses in the trauma patient: a multicenter trial. J Trauma 2001; 51:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/70\">",
"      Kirkpatrick AW, Baxter KA, Simons RK, et al. Intra-abdominal complications after surgical repair of small bowel injuries: an international review. J Trauma 2003; 55:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/71\">",
"      Demetriades D, Murray JA, Chan LS, et al. Handsewn versus stapled anastomosis in penetrating colon injuries requiring resection: a multicenter study. J Trauma 2002; 52:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/72\">",
"      Burch JM, Franciose RJ, Moore EE, et al. Single-layer continuous versus two-layer interrupted intestinal anastomosis: a prospective randomized trial. Ann Surg 2000; 231:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/73\">",
"      Maxwell RA, Fabian TC. Current management of colon trauma. World J Surg 2003; 27:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/74\">",
"      Nelson R, Singer M. Primary repair for penetrating colon injuries. Cochrane Database Syst Rev 2003; :CD002247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/75\">",
"      Demetriades D, Murray JA, Chan L, et al. Penetrating colon injuries requiring resection: diversion or primary anastomosis? An AAST prospective multicenter study. J Trauma 2001; 50:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/76\">",
"      Navsaria PH, Edu S, Nicol AJ. Civilian extraperitoneal rectal gunshot wounds: surgical management made simpler. World J Surg 2007; 31:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/77\">",
"      Velmahos GC, Gomez H, Falabella A, Demetriades D. Operative management of civilian rectal gunshot wounds: simpler is better. World J Surg 2000; 24:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/78\">",
"      Gonzalez RP, Falimirski ME, Holevar MR. The role of presacral drainage in the management of penetrating rectal injuries. J Trauma 1998; 45:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/79\">",
"      Stewart RM, Fabian TC, Croce MA, et al. Is resection with primary anastomosis following destructive colon wounds always safe? Am J Surg 1994; 168:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/80\">",
"      Cornwell EE 3rd, Velmahos GC, Berne TV, et al. The fate of colonic suture lines in high-risk trauma patients: a prospective analysis. J Am Coll Surg 1998; 187:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/81\">",
"      Velmahos GC, Vassiliu P, Demetriades D, et al. Wound management after colon injury: open or closed? A prospective randomized trial. Am Surg 2002; 68:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/82\">",
"      Talving P, Mohseni S, Inaba K, et al. Closed suction drain after isolated hollow viscus injury: a friend or foe? J Trauma 2011; 70:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/83\">",
"      Petrowsky H, Demartines N, Rousson V, Clavien PA. Evidence-based value of prophylactic drainage in gastrointestinal surgery: a systematic review and meta-analyses. Ann Surg 2004; 240:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/84\">",
"      Burch JM, Feliciano DV, Mattox KL. Colostomy and drainage for civilian rectal injuries: is that all? Ann Surg 1989; 209:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/85\">",
"      Thomas DD, Levison MA, Dykstra BJ, Bender JS. Management of rectal injuries. Dogma versus practice. Am Surg 1990; 56:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/86\">",
"      Tuggle D, Huber PJ Jr. Management of rectal trauma. Am J Surg 1984; 148:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/87\">",
"      Sagar PM, Couse N, Kerin M, et al. Randomized trial of drainage of colorectal anastomosis. Br J Surg 1993; 80:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/88\">",
"      Sagar PM, Hartley MN, Macfie J, et al. Randomized trial of pelvic drainage after rectal resection. Dis Colon Rectum 1995; 38:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/89\">",
"      Salim A, Teixeira PG, Inaba K, et al. Analysis of 178 penetrating stomach and small bowel injuries. World J Surg 2008; 32:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/90\">",
"      Faria GR, Almeida AB, Moreira H, et al. Prognostic factors for traumatic bowel injuries: killing time. World J Surg 2012; 36:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/57/26522/abstract/91\">",
"      Schn&uuml;riger B, Inaba K, Eberle BM, et al. Microbiological profile and antimicrobial susceptibility in surgical site infections following hollow viscus injury. J Gastrointest Surg 2010; 14:1304.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15700 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-555B9DE994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_57_26522=[""].join("\n");
var outline_f25_57_26522=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H909660042\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1065773\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H197204457\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H169106595\">",
"      Stomach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H169106603\">",
"      Small bowel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H169106611\">",
"      Colon and rectum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H533808630\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22697869\">",
"      Blunt injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22697876\">",
"      Penetrating injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H239075955\">",
"      Associated injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H239075588\">",
"      TRAUMA EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H538030155\">",
"      History and physical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H239076452\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H239077328\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H197204333\">",
"      INJURY GRADING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H538028240\">",
"      APPROACH TO MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H909659935\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H239078037\">",
"      Preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H197204297\">",
"      Abdominal exploration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H538028604\">",
"      Control of mesenteric bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H791235395\">",
"      Evaluating bowel viability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H791235263\">",
"      Management of intestinal injuries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H70383561\">",
"      - Repair techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H70383435\">",
"      - Repair by injury grade",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H629604702\">",
"      - Colorectal injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H538030097\">",
"      Abdominal closure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H791235782\">",
"      - Role of drains",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H538035352\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H75801689\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H75801954\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H909660042\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15700\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15700|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/42/43681\" title=\"diagnostic image 1\">",
"      Chance fracture of the lumbar spine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15700|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/59/41907\" title=\"figure 1\">",
"      Anatomy of the stomach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/19/38197\" title=\"figure 2\">",
"      Arcades and vasa recta of the small intestines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/14/43234\" title=\"figure 3\">",
"      Normal abdominal aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/6/31846\" title=\"figure 4\">",
"      Anatomic relationship of colon to surrounding structures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/32/41479\" title=\"figure 5\">",
"      Blood supply to the colon and rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/3/3127\" title=\"figure 6\">",
"      Venous drainage of the colon and rectum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15700|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/57/16285\" title=\"table 1\">",
"      AAST Organ Injury Scales",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/52/24397\" title=\"table 2\">",
"      Antimicrobial prophylaxis for gastrointestinal surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=related_link\">",
"      Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18425?source=related_link\">",
"      Blunt genitourinary trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18806?source=related_link\">",
"      Control measures to prevent surgical site infection following gastrointestinal procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3943?source=related_link\">",
"      Initial evaluation and management of abdominal gunshot wounds in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12776?source=related_link\">",
"      Initial evaluation and management of abdominal stab wounds in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=related_link\">",
"      Initial evaluation and management of blunt abdominal trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22266?source=related_link\">",
"      Management of duodenal and pancreatic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2218?source=related_link\">",
"      Management of patients with a colostomy or ileostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1097?source=related_link\">",
"      Management of the open abdomen in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31066?source=related_link\">",
"      Overview of inpatient management in the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/32/16904?source=related_link\">",
"      Penetrating trauma of the upper and lower genitourinary tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28009?source=related_link\">",
"      Recognition and management of diaphragmatic injury in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42473?source=related_link\">",
"      Spinal column injuries in adults: Definitions, mechanisms, and radiographs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_57_26523="Iron deficiency evolution";
var content_f25_57_26523=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F57739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F57739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Laboratory findings during the evolution of iron deficiency anemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Storage iron deficiency",
"       </td>",
"       <td class=\"subtitle1\">",
"        Iron-limited erythropoiesis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Iron-deficiency anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transferrin saturation*",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythrocyte protoporphyrin",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasma ferritin&bull;",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Transferrin saturation is calculated as the serum iron/total iron binding capacity (SI/TIBC).",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Ferritin is an acute phase reactant, and serum levels are increased by liver disease, inflammation, and malignancy. In these settings, it is not a good reflection of iron stores.",
"      <br/>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_57_26523=[""].join("\n");
var outline_f25_57_26523=null;
var title_f25_57_26524="ARR cut-off values";
var content_f25_57_26524=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F87570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F87570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ARR cut-off values, depending on assay and based on whether PAC, PRA, and DRC are measured in conventional or SI units",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        PRA",
"        <br/>",
"        (ng/mL x hour)",
"       </td>",
"       <td class=\"subtitle1\">",
"        PRA",
"        <br/>",
"        (pmol/L x minute)",
"       </td>",
"       <td class=\"subtitle1\">",
"        DRC*",
"        <br/>",
"        (mU/L)",
"       </td>",
"       <td class=\"subtitle1\">",
"        DRC*",
"        <br/>",
"        (ng/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        <strong>",
"         PAC",
"        </strong>",
"        (ng/dL)",
"       </td>",
"       <td class=\"centered\">",
"        20",
"       </td>",
"       <td class=\"centered\">",
"        1.6",
"       </td>",
"       <td class=\"centered\">",
"        2.4",
"       </td>",
"       <td class=\"centered\">",
"        3.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <strong>",
"         30",
"        </strong>",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        2.5",
"       </td>",
"       <td class=\"centered\">",
"        3.7",
"       </td>",
"       <td class=\"centered\">",
"        5.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        40",
"       </td>",
"       <td class=\"centered\">",
"        3.1",
"       </td>",
"       <td class=\"centered\">",
"        4.9",
"       </td>",
"       <td class=\"centered\">",
"        7.7",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         PAC",
"        </strong>",
"        (pmol/L)",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         750",
"        </strong>",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        60",
"       </td>",
"       <td class=\"centered\">",
"        91",
"       </td>",
"       <td class=\"centered\">",
"        144",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1000",
"       </td>",
"       <td class=\"centered\">",
"        80",
"       </td>",
"       <td class=\"centered\">",
"        122",
"       </td>",
"       <td class=\"centered\">",
"        192",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ARR: aldosterone-renin ratio; PAC: plasma aldosterone concentration; PRA: plasma renin activity; DRC: direct renin concentration; SI: Systeme International.",
"     <br/>",
"     * Values shown are on the basis of a conversion factor of PRA (ng/mL-hour) to DRC (mU/liter) of 8.2. DRC assays are still in evolution, and in a recently introduced and already commonly used automated DRC assay, the conversion factor is 12.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     The most commonly adopted cut-off values are shown in bold: 30 for PAC and PRA in conventional units (equivalent to 830 when PAC is in SI units) and 750 when PAC is expressed in SI units (equivalent to 27 in conventional units).",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:3266. Copyright &copy; 2008 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_57_26524=[""].join("\n");
var outline_f25_57_26524=null;
var title_f25_57_26525="Rx cytotoxic drug extravasation";
var content_f25_57_26525=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F67155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F67155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended treatment regimens for cytotoxic drug extravasations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        <p>",
"         Vinca alkaloids (vinblastine, vincristine, vinorelbine)",
"        </p>",
"        <p>",
"         Epidophyllotoxins (eg, etoposide)",
"        </p>",
"       </td>",
"       <td>",
"        Heat",
"       </td>",
"       <td>",
"        Topical",
"       </td>",
"       <td>",
"        15 to 20 minutes at least four times daily*",
"       </td>",
"       <td rowspan=\"2\">",
"        24 to 48 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyaluronidase",
"       </td>",
"       <td>",
"        Subcutaneously",
"       </td>",
"       <td>",
"        1 mL (150 units) as five separate injections of 0.2 mL each, each injected subcutaneously into the extravasated site using a separate 25 gauge or smaller needle*",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Anthracyclines (daunorubicin, doxorubicin, epirubicin, idarubicin)",
"       </td>",
"       <td>",
"        Cold",
"       </td>",
"       <td>",
"        Topical",
"       </td>",
"       <td>",
"        30 to 60 minutes, then every 15 minutes; discontinue at least 15 minutes prior to dexrazoxane therapy",
"       </td>",
"       <td>",
"        Day 1 only",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dexrazoxane",
"       </td>",
"       <td>",
"        Over 1 to 2 hours IV in a large vein away from the extravasation area*",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        1000 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        within six hours, 1000 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        after 24 hours, and 500 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        after 48 hours",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Liposomal anthracyclines (daunorubicin, doxorubicin)",
"       </td>",
"       <td>",
"        Cold",
"       </td>",
"       <td>",
"        Topical",
"       </td>",
"       <td>",
"        15 to 20 minutes at least four times daily",
"       </td>",
"       <td>",
"        24 hours",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Mitomycin",
"       </td>",
"       <td>",
"        Cold",
"       </td>",
"       <td>",
"        Topical",
"       </td>",
"       <td>",
"        15 to 20 minutes at least four times daily*",
"       </td>",
"       <td>",
"        24 hours",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Taxanes (docetaxel, paclitaxel)",
"       </td>",
"       <td>",
"        Cold",
"       </td>",
"       <td>",
"        Topical",
"       </td>",
"       <td>",
"        15 to 20 minutes at least four times daily*",
"       </td>",
"       <td>",
"        24 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyaluronidase",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Subcutaneously",
"       </td>",
"       <td>",
"        One time dose: 1 mL (150 units) as five separate injections of 0.2 mL each, each injected subcutaneously into the extravasated site using a separate 25 gauge or smaller needle*",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <p>",
"         Mechlorethamine",
"        </p>",
"        <p>",
"         Bendamustine",
"        </p>",
"        <p>",
"         Carboplatin",
"        </p>",
"        <p>",
"         Cisplatin",
"        </p>",
"        <p>",
"         Dacarbazine",
"        </p>",
"       </td>",
"       <td>",
"        Cold",
"       </td>",
"       <td>",
"        Topical",
"       </td>",
"       <td>",
"        For 6 to 12 hours following sodium thiosulfate antidote injection",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        6 to 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium thiosulfate",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Subcutaneously",
"       </td>",
"       <td>",
"        One time dose: inject 2 mL of the 1/6 Molar solution for each mg of mechlorethamine suspected to have extravasated",
"        <sup>",
"         &Delta;",
"        </sup>",
"        . Inject solution subcutaneously into the extravasation site using a 25 gauge or smaller needle.",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Other agents",
"       </td>",
"       <td>",
"        Cold",
"       </td>",
"       <td>",
"        Topical",
"       </td>",
"       <td>",
"        15 to 20 minutes at least four times daily",
"       </td>",
"       <td>",
"        24 hours",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <font class=\"bullet\">",
"      &bull;",
"     </font>",
"     Use of hyaluronidase for taxane extravasation recommended in guidelines from the EONS but not ONS.",
"     <br>",
"      &Delta; Sodium thiosulfate recommendation from ONS and EONS&nbsp;covers mechlorethamine extravasation only.",
"      <br>",
"       <font class=\"lozenge\">",
"        &loz;",
"       </font>",
"       Freshly prepared 1/6 Molar solution (approximately 4 percent; 4 mL 10 percent sodium thiosulfate &nbsp;+ 6 mL sterile water); recommended in guidelines from the ONS and EONS.",
"       <br>",
"        <br>",
"         EONS: European Oncology Nurses Society; ONS: US Oncology Nursing Society.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Perez Fidalgo JA, et al. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol 2012; 23 (7 suppl): vii:167.",
"       </li>",
"       <li>",
"        Polovich M, Whitford JM, Olsen M. Chemotherapy and biotherapy guidelines and recommendations for practice, 3rd ed, Oncology Nursing Society, Pittsburgh, PA, 2009. Section V: Immediate Complications of cytotoxic therapy, p.105.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_57_26525=[""].join("\n");
var outline_f25_57_26525=null;
var title_f25_57_26526="Contents: Adult trauma";
var content_f25_57_26526=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?10/42/10926\">",
"       Adult and Pediatric Emergency Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Adult trauma",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Adult trauma",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Abdominal trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/54/3943\">",
"           Initial evaluation and management of abdominal gunshot wounds in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/30/12776\">",
"           Initial evaluation and management of abdominal stab wounds in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/5/19545\">",
"           Initial evaluation and management of blunt abdominal trauma in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Burns",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/53/17242\">",
"           Emergency care of moderate and severe thermal burns in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/19/4410\">",
"           Environmental electrical injuries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/33/11801\">",
"           Topical chemical burns",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/38/37479\">",
"           Treatment of minor thermal burns",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Domestic violence",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/15/6393\">",
"           Intimate partner violence: Diagnosis and screening",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/41/5784\">",
"           Intimate partner violence: Epidemiology and health consequences",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/54/14183\">",
"           Intimate partner violence: Intervention and patient management",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/30/7658\">",
"           Emergency ultrasound in adults with abdominal and thoracic trauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/19/4410\">",
"           Environmental electrical injuries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/55/29562\">",
"           Initial evaluation and management of shock in adult trauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/11/35002\">",
"           Initial management of trauma in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/4/17482\">",
"           Prehospital care of the adult trauma patient",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Genitourinary trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/63/18425\">",
"           Blunt genitourinary trauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/32/16904\">",
"           Penetrating trauma of the upper and lower genitourinary tract",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Head and neck trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/11/26810\">",
"           Acute traumatic spinal cord injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/25/29079\">",
"           Assessment and management of auricular hematoma and cauliflower ear",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/59/29626\">",
"           Concussion and mild traumatic brain injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/29/5593\">",
"           Evaluation and management of middle ear trauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/49/7962\">",
"           Facial trauma in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/2/35882\">",
"           Management of acute severe traumatic brain injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/34/8745\">",
"           Open globe injuries: Emergent evaluation and initial management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/35/9783\">",
"           Orbital fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/62/2026\">",
"           Penetrating neck injuries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/25/3481\">",
"           Skull fractures in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Musculoskeletal trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/57/8090\">",
"           Acute compartment syndrome of the extremities",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pelvic trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/2/33831\">",
"           Minor pelvic fractures in the elderly",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/7/22650\">",
"           Pelvic trauma: Initial evaluation and management",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sexual violence",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/7/20601\">",
"           Evaluation and management of adult sexual assault victims",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Spinal trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/11/26810\">",
"           Acute traumatic spinal cord injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/34/31274\">",
"           Evaluation and acute management of cervical spinal column injuries in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/14/12520\">",
"           Evaluation of thoracic and lumbar spinal column injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/30/42473\">",
"           Spinal column injuries in adults: Definitions, mechanisms, and radiographs",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thoracic trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/47/27385\">",
"           Cardiac injury from blunt trauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/39/34426\">",
"           Initial evaluation and management of blunt thoracic trauma in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/37/28247\">",
"           Initial evaluation and management of chest wall trauma in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/21/23898\">",
"           Initial evaluation and management of penetrating thoracic trauma in adults",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-088494CEA8-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f25_57_26526=[""].join("\n");
var outline_f25_57_26526=null;
var title_f25_57_26527="Lipodermatosclerosis";
var content_f25_57_26527=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lipodermatosclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 192px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patients exhibits features of severe&nbsp;venous insufficiency combined with lymphedema. Chronic venous insufficiency may result in lipodermatosclerosis, a fibrosing panniculitis characterized by advanced hyperpigmentation and induration, in this case&nbsp;involving most of the leg circumferentially.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Patrick C Alguire, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_57_26527=[""].join("\n");
var outline_f25_57_26527=null;
